

BMJ Open

Effectiveness of pharmacotherapy for smoking cessation in the general population: Duration of use matters

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006229
Article Type:	Research
Date Submitted by the Author:	25-Jul-2014
Complete List of Authors:	Siahpush, Mohammad; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Shaikh, Raees; College of Public Health - University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health McCarthy, Molly; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Sikora, Asia; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Tibbits, Melissa; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Singh, Gopal; Health Resources and Services Administration, Maternal and Child Health Bureau, US Department of Health and Human Services
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Addiction, Public health
Keywords:	PREVENTIVE MEDICINE, PUBLIC HEALTH, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Effectiveness of pharmacotherapy for smoking cessation in the general population:
Duration of use matters**

Mohammad Siahpush, PhD

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Corresponding author:

Raees A. Shaikh, MPH

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
Email: raees.shaikh@unmc.edu | Tel: 402-559-1936 | Fax: 402-559-3773

Molly McCarthy, MPH

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Asia Sikora, PhD

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Melissa Tibbits, PhD

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Gopal K. Singh, Ph.D., M.S., M.Sc.

U.S. Department of Health & Human Services
5600 Fishers lane, Room 18-41 | Rockville, MD 20857 | USA

Word Count: 2582

Key Words: Pharmacotherapy for Cessation, Duration of Pharmacotherapy, Smoking Cessation, Assisted Cessation

ABSTRACT

Aim: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the United States, controlling for nicotine dependence and sociodemographic variables.

Methods: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker one year prior to the survey (n = 8 263). Respondents were asked about duration of use of prescription medication (Varenicline, Bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray, and inhaler) for smoking cessation.

Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found overwhelming evidence ($p < 0.001$) for an association between duration of pharmacotherapy use and smoking cessation. Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than five weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioral counseling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively.

Conclusion: Pharmacotherapies for smoking cessation can be effective in the general population if used for at least five weeks. Encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of a successful cessation.

ARTICLE SUMMARY

Strengths and limitations of the study:

- This was the first population-based study to examine the duration of use of prescription medication as well as NRT for smoking cessation as a predictor of successful smoking cessation, controlling for nicotine dependence and sociodemographic variables.
- A strength of this study was that it used a large nationally representative sample with a relatively high response rate.
- Our results strengthen the findings of clinical trials about the efficacy of pharmacotherapy for smoking cessation and indicate that these aids could also be effective in the general population if they are used for at least five weeks.
- Recall bias, especially related to the smokers previous quit attempts and the observational nature of the study precluding the establishment of a causal link were between the duration of pharmacotherapy use and successful smoking cessation, were the major limitations of this study.

INTRODUCTION

1
2
3
4
5 Clinical trials provide strong evidence that pharmacotherapy for smoking cessation
6
7 including various forms of nicotine replacement therapies (NRT), Bupropion, or Varenicline
8
9 greatly increase the chances of a successful smoking cessation attempt.[1, 2] However,
10
11 observational population-based studies have shown mixed results. While some have shown
12
13 that pharmacotherapy increases smoking cessation rates,[3-6] others have concluded the
14
15 opposite.[7-11] Yet, other population-based studies have shown no difference in cessation
16
17 rates between those who use and those who do not use pharmacotherapy.[12, 13] The
18
19 population-based reports that have found no favorable effect of pharmacotherapy have been
20
21 criticized for not controlling for nicotine dependence,[14-16] which is a predictor of abstinence
22
23 and is usually higher among smokers who choose to use pharmacotherapy for smoking
24
25 cessation.[4, 14, 17, 18] Some of the analyses that have controlled for nicotine dependence
26
27 have found a favorable effect of pharmacotherapy on smoking cessation[3, 4, 19] but others
28
29 have not.[7]

30
31
32 An additional confounder that rarely is taken into account in population-based studies is
33
34 duration of use of pharmacotherapy, which has been found to be associated with treatment
35
36 success in clinical trials.[20-22] We know of one population-based study which examined the
37
38 association of duration of use of pharmacotherapy with smoking cessation and found no
39
40 association.[12] This study was conducted in the US where NRT can be purchased over the
41
42 counter and medications such as Bupropion and Varenicline can only be obtained as
43
44 prescription drugs.
45
46
47
48
49
50
51
52
53
54

55 While clinical trials have high internal validity and can provide evidence for the efficacy
56
57 of pharmacotherapy, observational population-based studies can address effectiveness of these
58
59
60

1
2 therapies under conditions that they are intended to be used.[14] Furthermore, while clinical
3
4 trials provide confidence in causal associations, population-based studies are strong in
5
6 representativeness and external validity. Thus, both are needed to advance the science of
7
8 smoking cessation.[19]
9
10

11
12 There is no literature on population-based studies that examine the association of
13
14 duration of NRT and prescription medication use with smoking cessation. Our aim was to use a
15
16 large representative sample of the general population in the United States and investigate the
17
18 association of the duration of use of prescription medications and NRT with smoking cessation,
19
20 controlling for nicotine dependence and sociodemographic variables.
21
22
23

24 **METHODS**

25 **Data**

26
27 We used data from the 2010-2011 Tobacco Use Supplement to the Current Population
28
29 Survey (TUS-CPS), sponsored by the National Cancer Institute and administered by the US
30
31 Census Bureau in May 2010, August 2010, and January 2011.[23] The TUS-CPS is administered
32
33 as a part of the CPS, which is a monthly national survey of representative households by the US
34
35 Census Bureau and the Bureau of Labor Statistics.[24] The TUS-CPS utilizes a multistage
36
37 probability sampling of individuals 15 years and older, from a sample of approximately 56,000
38
39 housing units, in turn selected from 792 primary sampling units. The average response rate for
40
41 CPS for the 3 months of surveys used in this study was 93%, whereas for the TUS it was 63%.
42
43
44
45
46
47
48
49

50 **Measures**

51 *Successful smoking cessation:*

52
53
54
55 Individuals who reported to have smoked at least 100 cigarettes in their entire life but
56
57 were not smoking at all at the time of the interview were considered to have successfully quit
58
59
60

1
2 smoking (n = 1 769). Those who reported to have quit within the last four weeks were excluded
3
4 from the analysis (n = 322). Individuals who reported to have smoked at least 100 cigarettes in
5
6 their entire life, were smoking every day at the time of the interview and had made a quit
7
8 attempt in the past year were considered to have failed in their quit attempt (n = 7 304).
9
10 Individuals who reported to have used both prescription medication and NRT for smoking
11
12 cessation were excluded from the analysis (n = 488) because after subdividing this group by
13
14 categories of duration of use for prescription medication and NRT, some of the subgroup
15
16 sample sizes were extremely small. The total sample size for the study was 8 263 respondents,
17
18 consisting of 1 379 who successfully quit smoking and 6 884 whose quit attempt was not
19
20 successful.
21
22
23
24
25

26
27 *Assisted quit attempt and duration of pharmacotherapy use:*
28

29
30 Both daily and former smokers were asked in three separate questions to indicate
31
32 whether, in their last quit attempt in the past year, they used a prescription pill called (a)
33
34 Chantix or Varenicline, (b) Zyban, Bupropion, or Wellbutrin, or (b) other prescription pills. They
35
36 were also asked in three separate questions to indicate whether, in their last quit attempt, they
37
38 used (a) a nicotine patch, (b) nicotine gum or nicotine lozenge, or (c) nicotine nasal spray or
39
40 nicotine inhaler. They were also asked to indicate how many days, weeks or months they used
41
42 these prescription and/or NRT medications. Furthermore, both daily and former smokers were
43
44 asked three separate questions about use of behavioral counseling in their last quit attempt in
45
46 the past year. They were asked if they used a (a) telephone helpline or quitline, (b) one-on-one
47
48 counseling or (c) stop smoking clinic, class or support group. Based on the questions about use
49
50 of prescription medication, NRT and behavioral counseling, we created the following two
51
52 categorical variables:
53
54
55
56
57
58
59
60

1
2 Method of quit attempt
3

- 4
- 5 • Prescription medication only
 - 6
 - 7 • Prescription medication and behavioral counseling
 - 8
 - 9
 - 10 • NRT only
 - 11
 - 12 • NRT and behavioral counseling
 - 13
 - 14 • Behavioral counseling only
 - 15
 - 16
 - 17 • Unassisted
 - 18
 - 19

20 Duration of use of pharmacotherapy
21

- 22
- 23 • Prescription medication: 5+ weeks
 - 24
 - 25 • Prescription medication: 3-4 weeks
 - 26
 - 27
 - 28 • Prescription medication: 1-2 weeks¹
 - 29
 - 30 • NRT: 5+ weeks
 - 31
 - 32
 - 33 • NRT: 3-4 weeks
 - 34
 - 35 • NRT: 1-2 weeks
 - 36
 - 37
 - 38 • Behavioral counseling only
 - 39
 - 40
 - 41 • Unassisted
 - 42

43 We categorized duration of use of pharmacotherapy based on a systematic review of
44 studies assessing adherence to smoking cessation medication.[20] In categorizing duration of
45 use, we made no distinction between whether or not the medication was combined with
46 behavioral counseling as this distinction was inconsequential in the analysis.
47
48
49
50
51

52
53 **Statistical analysis**
54

55 We used multivariable logistic regression models to compute adjusted odds ratios for
56 the association of the method of quit attempt and duration of use of pharmacotherapy with
57
58
59
60

1
2 successful smoking cessation. Sampling weights were taken into account in the computation of
3
4 parameter estimates. We computed p -values using the jackknife, which is an unbiased
5
6 estimator for a statistic and a data-dependent method to calculate standard errors.[25] All
7
8 models controlled for daily cigarette consumption (current daily consumption among daily
9
10 smokers, and daily consumption 12 months ago among former smokers), age, race/ethnicity,
11
12 education, occupation, and family income. In order to account for the missing income data, CPS
13
14 uses one of the three imputation methods, relational imputation, longitudinal edits, or hot deck
15
16 allocation. Details of these methods are described elsewhere.[26] In multivariable logistic
17
18 regression models, we omitted observations that had a missing value for any of the covariates.
19
20 This constituted 1.7% of the full sample in the analysis pertaining to the method of quit attempt
21
22 (n = 142) and 6.3% of the full sample in the analysis pertaining to duration of pharmacotherapy
23
24 use (n = 491). We used the logistic regression results to compute adjusted cessation rates by
25
26 method of quit attempt and duration of use of pharmacotherapy. These adjusted rates were
27
28 computed by fixing covariates at their means in the fitted models.[27]
29
30
31
32
33
34
35
36

37 RESULTS

38 Sample characteristics and bivariate associations

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Weighted sample characteristics and unadjusted smoking cessation rates across categories of each covariate

Variable	% in sample	% quit	p- value
Method of quit attempt			0.074
Prescription only	10.01	18.54	
Prescription plus behavioral support	1.14	23.8	
NRT only	18.26	14.32	
NRT plus behavioral support	2.54	18.98	
Behavioral only	1.36	18.59	
Unassisted	66.68	17.16	
Duration of pharmacotherapy use			<0.001
Prescription: 5+ weeks	4.9	34.38	
Prescription: 3-4 weeks	1.43	16.82	
Prescription: 1-2 weeks	1.89	15.28	
NRT: 5+ weeks	6.04	30.65	
NRT: 3-4 weeks	1.48	19.9	
NRT: 1-2 weeks	13.48	7.36	
Behavioral only	1.42	18.59	
Unassisted	69.36	17.16	
Cigarettes per day			<0.001
0-9	24.48	15.08	
10-14	30.04	12.58	
15-19	10.31	12.58	
20-29	29.23	21.83	
30+	5.93	29.59	
Sex			0.975
Female	50.12	16.99	
Male	49.88	17.02	
Age			< 0.001
18-24	11.79	15.32	
25-39	33.08	18.17	
40-54	32.33	14.49	
55+	22.8	19.77	
Race/Ethnicity			0.003
Non-Hispanic White	76.17	17.99	
Non-Hispanic Black	11.34	12.98	
Hispanic	7.39	15.73	
Other	5.09	13.15	
Education			<0.001
Less than high school	15.25	13.15	
High school diploma	73.34	16.74	
Bachelor's degree	11.41	23.91	
Occupation			<0.001
Professional	14.33	20.99	
Service	12.31	13.96	
Sales	14.5	18.45	
Farming/construction/production	17.28	13.08	
Unemployed	12.01	13.81	
Not in labor force	29.57	19.24	
Family income			<0.001
<\$25,000	36.27	13.94	
\$25,000-\$49,000	31.65	17.21	
\$50,000-\$99,000	23.86	19.63	
\$100,000+	8.23	22.17	
Full sample		17.01	

Note: Sample size for each covariate varies from 7 820 to 8 263 depending on the number of missing values for that covariate.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Weighted sample characteristics are shown in Table 1. About 66.7% of the sample reported to have made an unassisted quit attempt; 10% used only prescription medication; 1.1% used prescription medication plus behavioral counseling; 18.2% used only NRT; 2.5% used NRT plus behavioral therapy; and 1.3% used only behavioral counseling. When broken down by duration of use, while most of those who used prescription medication did so for five or more weeks, the great majority of those who used NRT did so for 2 weeks or less. The reported number of cigarettes smoked per day was 14 or less for about 54.5% of the sample. Age was distributed with 11.8% of the sample under 25 years of age, 33% between 25-39 years, 32.3% between 40-54 years, and 22.8% 55 years or older. The sample was 76% non-Hispanic white, 11.3% non-Hispanic Black, 7.4% Hispanic, and 5% of other race/ethnicity. About 15.2% of the sample did not have a high school diploma, 73.3% had high school diploma, and 11.4% had at least a bachelor's degree. The distribution of family income was skewed such that over a third of the sample had an income of less than \$25 000 and less than a tenth of the sample had an income of \$100 000 or greater.

Table 1 also provides smoking cessation rates across categories of each covariate, indicating bivariate (unadjusted) associations between the covariates and quitting. Cessation rate was 17% in the whole sample. There was very little evidence that method of quit attempt was associated with cessation rate ($p < 0.074$). However, there was overwhelming evidence that duration of pharmacotherapy use was associated with quitting ($p < 0.001$) such that the use of prescription medication or NRT for 5+ weeks was associated with remarkably higher cessation rates compared to the use of these products for shorter durations, behavioral counseling or unassisted quit attempts. Number of cigarettes smoked per day had a curvilinear relationship with cessation such that those who smoked 0-9 cigarettes and those who smoked 20+ cigarettes per day had a higher cessation rate than others ($P < 0.001$). Age had a curvilinear relationship with cessation in that individuals in the 25-39 and 55+ age categories had notably higher cessation rates than others ($p < 0.001$). Race/ethnicity was associated with quitting such that Non-Hispanic Whites had the highest and non-Hispanic Blacks had the lowest cessation rates ($p = 0.003$). Higher socioeconomic status as measured by education, occupation, and income was associated with a higher cessation rate ($p < 0.001$ for all three indicators of socioeconomic status). Sex had no association with cessation.

Adjusted results from multivariable logistic regression models

Table 2. Adjusted^a odds ratios and 95% confidence intervals (CI) for the association of method of quit attempt and duration of pharmacotherapy use with the probability of successful smoking cessation

	OR (95% CI)	p-value
Method of quit attempt (n = 8 121)		0.025
Prescription only	1.00	
Prescription plus behavioral support	1.42 (0.76-2.66)	
NRT only	0.78 (0.59-1.02)	
NRT plus behavioral support	1.17 (0.73-1.86)	
Behavioral only	1.06 (0.57-1.97)	
Unassisted	1.09 (0.87-1.37)	
Duration of pharmacotherapy use (n = 7 772)		< 0.001
Prescription: 5+ weeks	1.00	
Prescription: 3-4 weeks	0.42 (0.21-0.84)	
Prescription: 1-2 weeks	0.38 (0.22-0.66)	
NRT: 5+ weeks	0.95 (0.67-1.36)	
NRT: 3-4 weeks	0.53 (0.29-0.97)	
NRT: 1-2 weeks	0.16 (0.11-0.24)	
Behavioral only	0.47 (0.25-0.90)	
Unassisted	0.48 (0.37-0.64)	

^a Adjusted for the effect of number of cigarettes smoked per day, sex, age, race/ethnicity, education, occupation, and family income.

Figure 1 here.....

Table 2 provides adjusted odds ratios for the association of method of quit attempt with the probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence of an association between quitting method and successful cessation, the adjusted results revealed some evidence of an association ($p = 0.025$). The highest cessation rate was among those who used prescription medication and behavioral counseling (20.4%) followed by those who used NRT and behavioral counseling (17.4%), attempted to quit unassisted (16.4%), used behavioral counseling only (16.1%), and those who used prescription medication only (15.3%). The lowest cessation rate was among those who only used NRT as a quitting method (12.3%).

Figure 2 here.....

Table 2 also provides adjusted odds ratios for the association of duration of pharmacotherapy use with the probability of smoking cessation. Figure 2 shows the adjusted cessation rates for various durations of pharmacotherapy use. Consistent with the unadjusted results in Table 1, the adjusted results provide strong evidence ($p < 0.001$) of an association between duration of pharmacotherapy use and successful cessation. Those who used prescription medication for 5+ weeks or NRT for 5+ weeks had higher cessation rates, 28.8%

1
2 and 27.8% respectively, than others. Cessation rates for those who used prescription
3 medication or NRT for less than five weeks varied from 6.2% to 14.5%. Cessation rates for those
4 who used only behavioral counseling and those who attempted to quit smoking unassisted
5 were 16.1% and 16.4%, respectively.
6
7

8
9 The results pertaining to the association of other covariates with successful cessation
10 were very similar in the multivariable regression models for method of quit attempt and
11 duration of pharmacotherapy use. These results were consistent with bivariate associations
12 reported above, except for the fact that there was very little evidence for an association of
13 race/ethnicity and smoking cessation in multivariable analyses.
14
15
16
17
18

19 DISCUSSION

20
21 This is the first population-based study to examine the duration of use of prescription
22 medication as well as NRT for smoking cessation as a predictor of successful smoking cessation.
23 We found that using pharmacotherapy for five weeks or longer is associated with a remarkably
24 higher probability of cessation compared to using pharmacotherapy for shorter durations, only
25 using behavioral counseling or trying to quit unassisted.
26
27
28
29
30

31 Our findings are consistent with the results of a study of a hospital-based cessation
32 program where participants who used NRT for 5 weeks or longer were found to have a higher
33 cessation rate at 6-month follow-up.[28] However, our findings are not consistent with those of
34 a population-based study which did not find any evidence that using NRT for more than 6
35 weeks versus not using NRT at all was associated with smoking cessation.[12] In that study, the
36 survey response rate was low, the sample size was small and prescription medications were not
37 examined. These factors could explain the discrepant findings.
38
39
40
41
42
43

44 While we found that smokers who used pharmacotherapy for at least 5 weeks have a far
45 more favorable outcome than others, only 11% of the sample was in this group and notably
46 about 70% of the sample did not use any pharmacotherapy for smoking cessation. Previous
47 research indicates that barriers to the use of these cessation aids include concerns with their
48 addictiveness, cost and side effects, as well as the belief that a treatment of any kind is not
49 needed to quit smoking.[29-31]
50
51
52
53
54
55

56 A weakness of the study relates to the fact that smokers forget many quit attempts [7,
57 32] and they are more prone to recall attempts that used pharmacotherapy than those that did
58
59
60

1
2 not.[14, 17] Such recall bias can underestimate the success rate of attempts at quitting with the
3 aid of pharmacotherapy.[17] Another limitation of the study is that because of its observational
4 nature, our study cannot establish a causal link between the duration of pharmacotherapy use
5 and successful smoking cessation. While our analyses controlled for several important
6 predictors of cessation including daily cigarette consumption, age, race, education, occupation,
7 and income, it is possible that there is residual confounding related to variables such as
8 depression, anxiety, alcohol use, and financial stress.[33, 34] Such confounding would further
9 weaken the ability of the study to imply causation. Moreover, there is a possibility of reverse
10 causation such that relapse would determine duration of pharmacotherapy use rather than vice
11 versa.[35] Smokers who use Varenicline to quit smoking are asked to completely stop smoking
12 one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a
13 short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit
14 attempt would cause a short duration of pharmacotherapy use instead of the reverse.
15
16
17
18
19
20
21
22
23
24
25

26 A strength of this study was that it used a large nationally representative sample with a
27 relatively high response rate. This was the first time that questions about the duration of
28 pharmacotherapy use were included in the TUS-CPS. We know of no other national data on the
29 general population that provide information on this variable. Many population-based studies of
30 pharmacotherapies for smoking cessation have found these aids to be ineffective. It is likely
31 that if these studies were able to account for duration of use, their findings would have been
32 different. However, data on duration of use is not routinely collected and it would require a
33 large sample size to provide a reliable estimate of the effect of using these medications for
34 duration of a few weeks. Nonetheless, it would likely be an important area for further research
35 to establish the relationship between duration of use of pharmacotherapy and successful
36 quitting in the general population.
37
38
39
40
41
42
43
44
45
46

47 Our results strengthen the findings of clinical trials about the efficacy of
48 pharmacotherapy for smoking cessation and indicate that these aids also be effective in the
49 general population if they are used for at least five weeks. Smokers who intend to quit should
50 be encouraged to use pharmacotherapy and adhere to their recommended duration of use.
51
52
53
54
55
56
57
58
59
60

CONTRIBUTORSHIP STATEMENT

We assure that all authors included on a paper fulfill the criteria of authorship. All have contributed in the conception and design, analysis and interpretation of data, drafting of the article and revising it critically for important intellectual content, and final approval of the version to be published. In addition we also assure that there is no one else who fulfills the criteria but has not been included as an author. Dr. Mohammad Siahpush was instrumental in conceptualization of research study, data analysis, and writing of the initial draft of the manuscript. Raees Shaikh and Molly McCarthy contributed in the development of study, data analysis, and preparation of the results section. They also helped with writing the manuscript and editing it for final submission. Dr. Asia Sikora helped with literature review, provided inputs for the materials and method section, and contributed to writing and editing the manuscript. Dr. Melissa Tibbits was involved with literature review and data analysis and provided her inputs to the entire manuscript. Dr. Gopal Singh was involved with formulation of research study and helped in the data analysis and contributed in the writing and editing of the final manuscript.

DETAILS OF FUNDING

This work did not require or receive funding.

CONFLICT OF INTEREST STATEMENT

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) declare that no support was received from any organization for the submitted work and that there was no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, neither did we have other relationships or activities that could appear to have influenced the submitted work.

ETHICAL APPROVAL STATEMENT

No ethical approval was required for this work.

DATA SHARING STATEMENT

No additional data used or available.

FIGURE LEGENDS

Figure1: Adjusted Cessation Rate by Method of Quit Attempt

Figure2: Adjusted Cessation Rate by Duration of Pharmacotherapy Use

REFERENCES

- 1 Raupach T, van Schayck C,P. Pharmacotherapy for smoking cessation: current advances and research topics. *CNS Drugs* 2011;**25**(5):371-82.
- 2 Cahill K, Stevens S, Lancaster T. Pharmacological Treatments for Smoking Cessation. *JAMA* 2014;**311**(2):193-4.
- 3 Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2013;**108**(1):193-202.
- 4 West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. *Thorax* 2007;**62**(11):998-1002.
- 5 Cummings KM, Fix B, Celestino P, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. *Journal of Public Health Management and Practice* 2006;**12**(1):37-43.
- 6 Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. *Lancet* 2005;**365**:1849-54.
- 7 Shiffman S, Brockwell SE, Pillitteri JL, et al. Use of smoking-cessation treatments in the United States. *American Journal of Preventive Medicine* 2008;**34**(2):102-11.
- 8 Alberg AJ, Patnaik JL, May JW, et al. Nicotine replacement therapy use among a cohort of smokers. *Journal of addictive diseases* 2005;**24**(1):101-13.
- 9 Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. *American Journal of Public Health* 2007;**97**(8):1503-9.
- 10 Hagimoto A, Nakamura M, Morita T, et al. Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. *Addiction* 2010;**105**(1):164-73.
- 11 Yang J, Hammond D, Driezen P, et al. The use of cessation assistance among smokers from China: Findings from the ITC China Survey. *BMC public health* 2011;**11**(1):75.
- 12 Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. *Tobacco control* 2013;**22**(1):32-7.
- 13 Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *Jama* 2002;**288**(10):1260-4.
- 14 Hughes JR, Peters EN, Naud S. Effectiveness of over-the-counter nicotine replacement therapy: a qualitative review of nonrandomized trials. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2011;**13**(7):512-22.
- 15 Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. *Drug and Alcohol Review* 2008;**27**(5):529-47.

- 1
2 16 Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the
3 succeeding. *Tobacco control* 2009;**18**(1):43-6.
4
5
6 17 Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may
7 underestimate the effectiveness of stop-smoking medications. *Nicotine & Tobacco Research*
8 2012;**14**(12):1483-7.
9
10 18 Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy.
11 *Tobacco control* 2005;**14**(5):346-55.
12
13
14 19 Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population
15 study. *Addiction (Abingdon, England)* 2014;**109**(3):491-9.
16
17 20 Raupach T, Brown J, Herbec A, et al. A systematic review of studies assessing the association between
18 adherence to smoking cessation medication and treatment success. *Addiction* 2014;**109**(1):35-43.
19
20
21 21 Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch
22 use and treatment efficacy: Secondary analysis of a 10 week randomized, double-blind, placebo-
23 controlled clinical trial simulating over-the-counter use in adult smokers. *Clinical therapeutics*
24 2008;**30**(10):1852-8.
25
26
27 22 Lee JH, Jones PG, Bybee K, et al. A longer course of varenicline therapy improves smoking cessation
28 rates. *Preventive cardiology* 2008;**11**(4):210-4.
29
30
31 23 U.S. Department of Commerce, Census Bureau. National Cancer Institute and Centers for Disease
32 Control and Prevention Co-sponsored Tobacco Use Supplement to the Current Population Survey (2010-
33 2011). 2012;.
34
35 24 U.S. Census Bureau. Current population survey: Design and methodology. *Technical Paper TP63RV,*
36 *Bureau of Labor Statistics and US Census Bureau, Washington DC* October 2006;**2014**(February 10).
37
38
39 25 Gould W. Jackknife estimation. *Stata Technical Bulletin* 1995;**4**(24).
40
41
42 26 The U.S. Census Bureau. Current Population Survey: Imputation of Unreported Data Items.
43 2014;**2014**(03/18).
44
45
46 27 Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal
47 effects. *Stata Journal* 2012;**12**(2).
48
49
50 28 Raupach T, Shahab L, Neubert K, et al. Implementing a hospital-based smoking cessation programme:
51 evidence for a learning effect. *Patient education and counseling* 2008;**70**(2):199-204.
52
53
54 29 Fu SS, Burgess D, van Ryn M, et al. Views on smoking cessation methods in ethnic minority
55 communities: a qualitative investigation. *Preventive medicine* 2007;**44**(3):235-40.
56
57
58 30 Ryan KK, Garrett-Mayer E, Alberg AJ, et al. Predictors of cessation pharmacotherapy use among black
59 and non-Hispanic white smokers. *Nicotine & tobacco research : official journal of the Society for*
60 *Research on Nicotine and Tobacco* 2011;**13**(8):646-52.

1
2 31 Cokkinides VE, Ward E, Jemal A, et al. Under-use of smoking-cessation treatments: results from the
3 National Health Interview Survey, 2000. *American Journal of Preventive Medicine* 2005;**28**(1):119-22.

4
5
6 32 Berg CJ, An LC, Kirch M, et al. Failure to report attempts to quit smoking. *Addictive Behaviors*
7 2010;**35**(10):900-4.

8
9 33 Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. *Respiratory*
10 *medicine* 2008;**102**(8):1182-92.

11
12 34 Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective
13 study of an Australian national sample. *Addiction* 2006;**110**:121-7.

14
15
16 35 Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction*
17 2007;**102**(5):809-14.

18
19
20 36 Pfizer Inc. Getting started with CHANTIX: Things to Remember. 2014;**2014**(March 2014).




Figure1: Adjusted Cessation Rate by Method of Quit Attempt.

view only




Figure 2: Adjusted Cessation Rate by Duration of Pharmacotherapy Use

STROBE Statement Checklist

	Checklist
Title and abstract	Yes
Introduction	
Background/rationale	Yes
Objectives/Aims	Yes
Methods	
Data sources	Yes
Measurement	Yes
Statistical methods	Yes
Results	
Descriptive data	Yes
Main results	Yes
Discussion	
Key results	Yes
Interpretation	Yes
Generalizability/Strengths	Yes
Limitations	Yes
Other information	
Funding	Yes
Competing Interest Statement:	Yes
Ethical Approval Statement	Yes
Contributorship Statement	Yes

BMJ Open

Effectiveness of pharmacotherapy for smoking cessation in the general population: Duration of use matters

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006229.R1
Article Type:	Research
Date Submitted by the Author:	03-Dec-2014
Complete List of Authors:	Siahpush, Mohammad; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Shaikh, Raees; College of Public Health - University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health McCarthy, Molly; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Sikora, Asia; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Tibbits, Melissa; University of Nebraska Medical Center, Department of Health Promotion, Social and Be; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Singh, Gopal; Health Resources and Services Administration, Maternal and Child Health Bureau, US Department of Health and Human Services
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Addiction, Public health
Keywords:	PREVENTIVE MEDICINE, PUBLIC HEALTH, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts

**Association between duration of use and success of pharmacotherapy for smoking cessation:
Findings from a national survey**

Mohammad Siahpush, PhD

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Corresponding author:

Raees A. Shaikh, MPH

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
Email: raees.shaikh@unmc.edu | Tel: 402-559-1936 | Fax: 402-559-3773

Molly McCarthy, MPH

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Asia Sikora Kessler, PhD

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Melissa Tibbits, PhD

Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Gopal K. Singh, Ph.D., M.S., M.Sc.

U.S. Department of Health & Human Services
5600 Fishers lane, Room 18-41 | Rockville, MD 20857 | USA

Word Count: 2496

Key Words: Pharmacotherapy for Smoking Cessation, Duration of Pharmacotherapy Use, Smoking Cessation, Assisted Cessation

ABSTRACT

Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the United States, controlling for nicotine dependence and sociodemographic variables.

Setting: United States

Participants: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker one year prior to the survey (n = 8 263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray, and inhaler) for smoking cessation.

Primary Outcome Measure: Successful Smoking Cessation

Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found evidence for an association ($p < 0.001$) between duration of pharmacotherapy use and smoking cessation. Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than five weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioral counseling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively.

Conclusion: Pharmacotherapies for smoking cessation can be effective in the general population if used for at least five weeks. Results suggest that encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of a successful cessation.

ARTICLE SUMMARY

Strengths and limitations of the study:

- This was the first population-based study to examine the association between the duration of use of prescription medication as well as NRT for smoking cessation and successful smoking cessation, controlling for nicotine dependence and sociodemographic variables.
- A strength of this study was that it used a large nationally representative sample with a relatively high response rate.
- Our results strengthen the findings of clinical trials about the efficacy of pharmacotherapy for smoking cessation and indicate that these aids might also be successful in the general population if they are used for at least five weeks.
- A strong possibility of reverse causation such that relapse would determine duration of pharmacotherapy use rather than vice versa, was a major limitation of this study. Recall bias, especially related to the smokers previous quit attempts and the observational nature of the study precluding the establishment of a causal link were between the duration of pharmacotherapy use and successful smoking cessation, were the other limitations.

INTRODUCTION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Clinical trials provide strong evidence that pharmacotherapy for smoking cessation including various forms of nicotine replacement therapies (NRT), bupropion, or varenicline greatly increase the chances of a successful smoking cessation attempt.[1, 2] However, observational population-based studies have shown mixed results. While some have shown that pharmacotherapy increases smoking cessation rates,[3-6] others have concluded the opposite.[7-11] Yet, other population-based studies have shown no difference in cessation rates between those who use and those who do not use pharmacotherapy.[12, 13] The population-based reports that have found no favorable effect of pharmacotherapy have been criticized for not controlling for nicotine dependence,[14-16] which is a predictor of abstinence and is usually higher among smokers who choose to use pharmacotherapy for smoking cessation.[4, 14, 17, 18] Some of the analyses that have controlled for nicotine dependence have found a favorable effect of pharmacotherapy on smoking cessation[3, 4, 19] but others have not.[7]

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
An additional confounder that rarely is taken into account in population-based studies is duration of use of pharmacotherapy, which has been found to be associated with treatment success in clinical trials.[20-22] We know of one population-based study which examined the association of duration of use of pharmacotherapy with smoking cessation and found no association.[12] This study was conducted in the US where NRT can be purchased over the counter and medications such as bupropion and varenicline can only be obtained as prescription drugs.

53
54
55
56
57
58
59
60
While clinical trials have high internal validity and can provide evidence for the efficacy of pharmacotherapy, observational population-based studies can address effectiveness of these

1 therapies under conditions that they are intended to be used.[14] Furthermore, while clinical
2
3 trials provide confidence in causal associations, population-based studies are strong in
4
5 representativeness and external validity. Thus, both are needed to advance the science of
6
7 smoking cessation.[19]
8
9

10
11 There is no literature on population-based studies that examine the association of
12
13 duration of NRT and prescription medication use with smoking cessation. Our aim was to use a
14
15 large representative sample of the general population in the United States and investigate the
16
17 association of the duration of use of prescription medications and NRT with smoking cessation,
18
19 controlling for nicotine dependence and sociodemographic variables.
20
21
22

23 METHODS

24 Data

25
26 We used data from the 2010-2011 Tobacco Use Supplement to the Current Population
27
28 Survey (TUS-CPS), sponsored by the National Cancer Institute and administered by the US
29
30 Census Bureau in May 2010, August 2010, and January 2011.[23] The TUS-CPS is administered
31
32 as a part of the CPS, which is a monthly national survey of representative households by the US
33
34 Census Bureau and the Bureau of Labor Statistics.[24] The TUS-CPS utilizes a multistage
35
36 probability sampling of individuals 15 years and older, from a sample of approximately 56,000
37
38 housing units, in turn selected from 792 primary sampling units. The average response rate for
39
40 CPS for the 3 months of surveys used in this study was 93%, whereas for the TUS it was 63%.
41
42
43
44
45
46
47

48 Measurement

49 *Successful smoking cessation:*

50
51
52 Individuals who reported to have smoked at least 100 cigarettes in their entire life but
53
54 were not smoking at all at the time of the interview and were a daily smoker one year prior to
55
56
57
58
59
60

1 the interview (“Around this time 12 months ago were you smoking everyday ...?”) were
2
3 considered to have successfully quit smoking (n = 1 769). Those who reported to have quit
4
5 within the last four weeks were excluded from the analysis (n = 322). Individuals who reported
6
7 within the last four weeks were excluded from the analysis (n = 322). Individuals who reported
8
9 to have smoked at least 100 cigarettes in their entire life, were smoking every day at the time
10
11 of the interview and had made a quit attempt in the past year were considered to have failed in
12
13 their quit attempt (n = 7 304). Individuals who reported to have used both prescription
14
15 medication and NRT for smoking cessation were excluded from the analysis (n = 488) because
16
17 after subdividing this group by categories of duration of use for prescription medication and
18
19 NRT, some of the subgroup sample sizes were extremely small. The total sample size for the
20
21 study was 8 263 respondents, consisting of 1 379 who successfully quit smoking and 6 884
22
23 whose quit attempt was not successful.
24
25
26
27

28 *Assisted quit attempt and duration of pharmacotherapy use:*
29

30
31 Both daily and former smokers were asked in three separate questions to indicate
32
33 whether, in their last quit attempt in the past year, they used a prescription pill called (a)
34
35 Chantix or varenicline, (b) zyban, bupropion, or wellbutrin, or (b) other prescription pills. They
36
37 were also asked in three separate questions to indicate whether, in their last quit attempt in
38
39 the past year, they used (a) a nicotine patch, (b) nicotine gum or nicotine lozenge, or (c)
40
41 nicotine nasal spray or nicotine inhaler. They were also asked to indicate how many days,
42
43 weeks or months they used these prescription and/or NRT medications. Furthermore, both
44
45 daily and former smokers were asked three separate questions about use of behavioral
46
47 counseling in their last quit attempt in the past year. They were asked if they used a (a)
48
49 telephone helpline or quitline, (b) one-on-one counseling or (c) stop smoking clinic, class or
50
51
52
53
54
55
56
57
58
59
60

1 support group. Based on the questions about use of prescription medication, NRT and
2
3 behavioral counseling, we created the following two categorical variables:
4

5
6 Method of quit attempt
7

- 8 • Prescription medication only
- 9
- 10 • Prescription medication and behavioral counseling
- 11
- 12 • NRT only
- 13
- 14 • NRT and behavioral counseling
- 15
- 16 • Behavioral counseling only
- 17
- 18 • Unassisted
- 19
- 20
- 21
- 22
- 23

24 Duration of use of pharmacotherapy
25

- 26 • Prescription medication: 5+ weeks
- 27
- 28 • Prescription medication: 3-4 weeks
- 29
- 30 • Prescription medication: 1-2 weeks¹
- 31
- 32 • NRT: 5+ weeks
- 33
- 34 • NRT: 3-4 weeks
- 35
- 36 • NRT: 1-2 weeks
- 37
- 38 • Behavioral counseling only
- 39
- 40 • Unassisted
- 41
- 42
- 43
- 44
- 45
- 46

47 We categorized duration of use of pharmacotherapy based on a systematic review of
48 studies assessing adherence to smoking cessation medication.[20] In categorizing duration of
49 use, we made no distinction between whether or not the medication was combined with
50 behavioral counseling as this distinction was inconsequential in the analysis.
51
52
53
54
55

56
57 **Statistical analysis**
58
59
60

1 We used multivariable logistic regression models to compute adjusted odds ratios for
2
3 the association of the method of quit attempt and duration of use of pharmacotherapy with
4
5 successful smoking cessation. Sampling weights were taken into account in the computation of
6
7 parameter estimates. We computed p -values using the jackknife, which is an unbiased
8
9 estimator for a statistic and a data-dependent method to calculate standard errors.[25] All
10
11 models controlled for daily cigarette consumption (current daily consumption among daily
12
13 smokers, and daily consumption 12 months ago among former smokers), age, race/ethnicity,
14
15 education, occupation, and family income. In order to account for the missing income data, CPS
16
17 uses one of the three imputation methods, relational imputation, longitudinal edits, or hot deck
18
19 allocation. Details of these methods are described elsewhere.[26] In multivariable logistic
20
21 regression models, we omitted observations that had a missing value for any of the covariates.
22
23 This constituted 1.7% of the full sample in the analysis pertaining to the method of quit attempt
24
25 (n = 142) and 6.3% of the full sample in the analysis pertaining to duration of pharmacotherapy
26
27 use (n = 491). We used the logistic regression results to compute adjusted cessation rates by
28
29 method of quit attempt and duration of use of pharmacotherapy. These adjusted rates were
30
31 computed by fixing covariates at their means in the fitted models.[27]
32
33
34
35
36
37
38
39
40

41 RESULTS

42 Sample characteristics and bivariate associations

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Weighted sample characteristics and unadjusted smoking cessation rates across categories of each covariate

Variable	% in sample	% quit	p- value
Method of quit attempt			0.074
Prescription only	10.01	18.54	
Prescription plus behavioral support	1.14	23.8	
NRT only	18.26	14.32	
NRT plus behavioral support	2.54	18.98	
Behavioral only	1.36	18.59	
Unassisted	66.68	17.16	
Duration of pharmacotherapy use			<0.001
Prescription: 5+ weeks	4.9	34.38	
Prescription: 3-4 weeks	1.43	16.82	
Prescription: 1-2 weeks	1.89	15.28	
NRT: 5+ weeks	6.04	30.65	
NRT: 3-4 weeks	1.48	19.9	
NRT: 1-2 weeks	13.48	7.36	
Behavioral only	1.42	18.59	
Unassisted	69.36	17.16	
Cigarettes per day			<0.001
0-9	24.48	15.08	
10-14	30.04	12.58	
15-19	10.31	12.58	
20-29	29.23	21.83	
30+	5.93	29.59	
Sex			0.975
Female	50.12	16.99	
Male	49.88	17.02	
Age			< 0.001
18-24	11.79	15.32	
25-39	33.08	18.17	
40-54	32.33	14.49	
55+	22.8	19.77	
Race/Ethnicity			0.003
Non-Hispanic White	76.17	17.99	
Non-Hispanic Black	11.34	12.98	
Hispanic	7.39	15.73	
Other	5.09	13.15	
Education			<0.001
Less than high school	15.25	13.15	
High school diploma	73.34	16.74	
Bachelor's degree	11.41	23.91	
Occupation			<0.001
Professional	14.33	20.99	
Service	12.31	13.96	
Sales	14.5	18.45	
Farming/construction/production	17.28	13.08	
Unemployed	12.01	13.81	
Not in labor force	29.57	19.24	
Family income			<0.001
<\$25,000	36.27	13.94	
\$25,000-\$49,000	31.65	17.21	
\$50,000-\$99,000	23.86	19.63	
\$100,000+	8.23	22.17	
Full sample		17.01	

Note: Sample size for each covariate varies from 7 820 to 8 263 depending on the number of missing values for that covariate. P-values are based on chi-square tests.

1 Weighted sample characteristics are shown in Table 1. About 66.7% of the sample
2 reported to have made an unassisted quit attempt; 10% used only prescription medication;
3 1.1% used prescription medication plus behavioral counseling; 18.2% used only NRT; 2.5% used
4 NRT plus behavioral therapy; and 1.3% used only behavioral counseling. When broken down by
5 duration of use, while most of those who used prescription medication did so for five or more
6 weeks, the great majority of those who used NRT did so for 2 weeks or less. The reported
7 number of cigarettes smoked per day was 14 or less for about 54.5% of the sample. Age was
8 distributed with 11.8% of the sample under 25 years of age, 33% between 25-39 years, 32.3%
9 between 40-54 years, and 22.8% 55 years or older. The sample was 76% non-Hispanic white,
10 11.3% non-Hispanic Black, 7.4% Hispanic, and 5% of other race/ethnicity. About 15.2% of the
11 sample did not have a high school diploma, 73.3% had high school diploma, and 11.4% had at
12 least a bachelor's degree. The distribution of family income was skewed such that over a third
13 of the sample had an income of less than \$25 000 and less than a tenth of the sample had an
14 income of \$100 000 or greater.

15
16
17
18
19
20
21
22
23
24
25
26
27 Table 1 also provides smoking cessation rates across categories of each covariate,
28 indicating bivariate (unadjusted) associations between the covariates and quitting. Cessation
29 rate was 17% in the whole sample. There was very little evidence that method of quit attempt
30 was associated with cessation rate ($p < 0.074$). However, the duration of pharmacotherapy use
31 ($p < 0.001$), number of cigarettes smoked per day ($p < 0.001$), age ($p < 0.001$), and
32 race/ethnicity ($p = 0.003$) were all associated with quitting. Higher socioeconomic status as
33 measured by education, occupation, and income was associated with a higher cessation rate (p
34 < 0.001 for all three indicators of socioeconomic status). Sex had no association with cessation.
35
36
37
38
39
40
41
42
43

44 **Adjusted results from multivariable logistic regression models**

45
46 Table 2 provides adjusted odds ratios for the association of method of quit attempt with the
47 probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various
48 quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence
49 of an association between quitting method and successful cessation, the adjusted results
50
51
52
53
54
55
56
57
58
59
60

Table 2. Adjusted^a odds ratios and 95% confidence intervals (CI) for the association of method of quit attempt and duration of pharmacotherapy use with the probability of successful smoking cessation

	OR (95% CI)	p-value
Method of quit attempt (n = 8 121)		
Prescription only	1.00	
Prescription plus behavioral support	1.42 (0.76-2.66)	0.277
NRT only	0.78 (0.59-1.02)	0.072
NRT plus behavioral support	1.17 (0.73-1.86)	0.513
Behavioral only	1.06 (0.57-1.97)	0.844
Unassisted	1.09 (0.87-1.37)	0.464
Duration of pharmacotherapy use (n = 7 772)		
Prescription: 5+ weeks	1.00	
Prescription: 3-4 weeks	0.42 (0.21-0.84)	0.014
Prescription: 1-2 weeks	0.38 (0.22-0.66)	0.001
NRT: 5+ weeks	0.95 (0.67-1.36)	0.786
NRT: 3-4 weeks	0.53 (0.29-0.97)	0.040
NRT: 1-2 weeks	0.16 (0.11-0.24)	<0.001
Behavioral only	0.47 (0.25-0.90)	0.022
Unassisted	0.48 (0.37-0.64)	<0.001

^a Adjusted for the effect of number of cigarettes smoked per day, sex, age, race/ethnicity, education, occupation, and family income.

Figure 1 here.....

revealed some evidence of an association ($p = 0.025$). The highest cessation rate was among those who used prescription medication and behavioral counseling (20.4%) followed by those who used NRT and behavioral counseling (17.4%), attempted to quit unassisted (16.4%), used behavioral counseling only (16.1%), and those who used prescription medication only (15.3%). The lowest cessation rate was among those who only used NRT as a quitting method (12.3%).

Figure 2 here.....

Table 2 also provides adjusted odds ratios for the association of duration of pharmacotherapy use with the probability of smoking cessation. Figure 2 shows the adjusted cessation rates for various durations of pharmacotherapy use. Consistent with the unadjusted results in Table 1, the adjusted results in Table 2 also provide evidence ($p < 0.001$) of an association between duration of pharmacotherapy use and successful cessation. As shown in Figure 2, cessation rates were highest among those who used prescription medication for 5+ weeks (28.8%) and those who used NRT for 5+ weeks (27.8%). Cessation rates for those who used prescription medication or NRT for less than five weeks varied from 6.2% to 14.5%.

1 Cessation rates for those who used only behavioral counseling and those who attempted to
2 quit smoking unassisted were 16.1% and 16.4%, respectively.
3

4 The results pertaining to the association of other covariates with successful cessation
5 were very similar in the multivariable regression models for method of quit attempt and
6 duration of pharmacotherapy use. These results were consistent with bivariate associations
7 reported above, except for the fact that there was very little evidence for an association of
8 race/ethnicity and smoking cessation in multivariable analyses.
9
10
11
12
13

14 DISCUSSION

15 This is the first population-based study to examine the association of successful smoking
16 cessation and duration of use of prescription medication as well as NRT for smoking cessation.
17 We found that using pharmacotherapy for five weeks or longer is associated with a higher
18 probability of cessation compared to using pharmacotherapy for shorter durations, only using
19 behavioral counseling or trying to quit unassisted.
20
21
22
23
24
25
26
27

28 Our findings are consistent with the results of a study of a hospital-based cessation
29 program where participants who used NRT for 5 weeks or longer were found to have a higher
30 cessation rate at 6-month follow-up.[28] However, our findings are not consistent with those of
31 a population-based study which did not find any evidence that using NRT for more than 6
32 weeks versus not using NRT at all was associated with smoking cessation.[12] In that study, the
33 survey response rate was low, the sample size was small and prescription medications were not
34 examined. These factors could explain the discrepant findings.
35
36
37
38
39
40

41 While we found that smokers who used pharmacotherapy for at least 5 weeks have a far
42 more favorable outcome than others, only 11% of the sample was in this group and notably
43 about 70% of the sample did not use any pharmacotherapy for smoking cessation. Previous
44 research indicates that barriers to the use of these cessation aids include concerns with their
45 addictiveness, cost and side effects, as well as the belief that a treatment of any kind is not
46 needed to quit smoking.[29-31]
47
48
49
50
51

52 A major limitation of the study is that there is a strong possibility of reverse causation
53 such that relapse would determine duration of pharmacotherapy use rather than vice
54 versa.[35] Smokers who use varenicline to quit smoking are asked to completely stop smoking
55 one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a
56
57
58
59
60

1 short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit
2 attempt would cause a short duration of pharmacotherapy use instead of the reverse.
3
4 Furthermore, because of its observational nature, our study cannot establish a causal link
5 between the duration of pharmacotherapy use and successful smoking cessation. While our
6 analyses controlled for several important predictors of cessation including daily cigarette
7 consumption, age, race, education, occupation, and income, it is possible that there might be
8 residual confounding related to variables such as depression, anxiety, alcohol use, and financial
9 stress.[33, 34] Such confounding would further weaken the ability of the study to imply
10 causation.
11
12

13
14
15
16
17
18 Another weakness of the study relates to the fact that smokers forget many quit
19 attempts [7, 32] and they are more prone to recall attempts that used pharmacotherapy than
20 those that did not.[14, 17] Such recall bias can underestimate the success rate of attempts at
21 quitting with the aid of pharmacotherapy.[17]
22
23

24
25 A strength of this study was that it used a large nationally representative sample with a
26 relatively high response rate. This was the first time that questions about the duration of
27 pharmacotherapy use were included in the TUS-CPS. We know of no other national data on the
28 general population that provide information on this variable. Many population-based studies of
29 pharmacotherapies for smoking cessation have found these aids to be ineffective. It is likely
30 that if these studies were able to account for duration of use, their findings would have been
31 different. However, data on duration of use is not routinely collected and it would require a
32 large sample size to provide a reliable estimate of the effect of using these medications for
33 duration of a few weeks. Nonetheless, it would likely be an important area for further research
34 to establish the relationship between duration of use of pharmacotherapy and successful
35 quitting in the general population.
36
37
38
39
40
41
42
43
44
45

46 Our results strengthen the findings of clinical trials about the efficacy of
47 pharmacotherapy for smoking cessation and indicate that these aids might also be successful in
48 the general population if they are used for at least five weeks.
49
50
51
52
53
54
55
56
57
58
59
60

CONTRIBUTORSHIP STATEMENT

We assure that all authors included on a paper fulfill the criteria of authorship. All have contributed in the conception and design, analysis and interpretation of data, drafting of the article and revising it critically for important intellectual content, and final approval of the version to be published. In addition we also assure that there is no one else who fulfills the criteria but has not been included as an author. Dr. Mohammad Siahpush was instrumental in conceptualization of research study, data analysis, and writing of the initial draft of the manuscript. Raees Shaikh and Molly McCarthy contributed in the development of study, data analysis, and preparation of the results section. They also helped with writing the manuscript and editing it for final submission. Dr. Asia Sikora helped with literature review, provided inputs for the materials and method section, and contributed to writing and editing the manuscript. Dr. Melissa Tibbits was involved with literature review and data analysis and provided her inputs to the entire manuscript. Dr. Gopal Singh was involved with formulation of research study and helped in the data analysis and contributed in the writing and editing of the final manuscript.

DETAILS OF FUNDING

This work did not require or receive funding.

CONFLICT OF INTEREST STATEMENT

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) declare that no support was received from any organization for the submitted work and that there was no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, neither did we have other relationships or activities that could appear to have influenced the submitted work.

ETHICAL APPROVAL STATEMENT

No ethical approval was required for this work.

DATA SHARING STATEMENT

No additional data used or available.

FIGURE LEGENDS

Figure1: Adjusted Cessation Rate by Method of Quit Attempt

Figure2: Adjusted Cessation Rate by Duration of Pharmacotherapy Use

REFERENCES

- 1 Raupach T, van Schayck C,P. Pharmacotherapy for smoking cessation: current advances and research topics. *CNS Drugs* 2011;**25**(5):371-82.
- 2 Cahill K, Stevens S, Lancaster T. Pharmacological Treatments for Smoking Cessation. *JAMA* 2014;**311**(2):193-4.
- 3 Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2013;**108**(1):193-202.
- 4 West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. *Thorax* 2007;**62**(11):998-1002.
- 5 Cummings KM, Fix B, Celestino P, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. *Journal of Public Health Management and Practice* 2006;**12**(1):37-43.
- 6 Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. *Lancet* 2005;**365**:1849-54.
- 7 Shiffman S, Brockwell SE, Pillitteri JL, et al. Use of smoking-cessation treatments in the United States. *American Journal of Preventive Medicine* 2008;**34**(2):102-11.
- 8 Alberg AJ, Patnaik JL, May JW, et al. Nicotine replacement therapy use among a cohort of smokers. *Journal of addictive diseases* 2005;**24**(1):101-13.
- 9 Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. *American Journal of Public Health* 2007;**97**(8):1503-9.
- 10 Hagimoto A, Nakamura M, Morita T, et al. Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. *Addiction* 2010;**105**(1):164-73.
- 11 Yang J, Hammond D, Driezen P, et al. The use of cessation assistance among smokers from China: Findings from the ITC China Survey. *BMC public health* 2011;**11**(1):75.
- 12 Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. *Tobacco control* 2013;**22**(1):32-7.
- 13 Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *Jama* 2002;**288**(10):1260-4.
- 14 Hughes JR, Peters EN, Naud S. Effectiveness of over-the-counter nicotine replacement therapy: a qualitative review of nonrandomized trials. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2011;**13**(7):512-22.
- 15 Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. *Drug and Alcohol Review* 2008;**27**(5):529-47.

- 1 16 Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the
2 succeeding. *Tobacco control* 2009;**18**(1):43-6.
- 3
4 17 Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may
5 underestimate the effectiveness of stop-smoking medications. *Nicotine & Tobacco Research*
6 2012;**14**(12):1483-7.
- 7
8 18 Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy.
9 *Tobacco control* 2005;**14**(5):346-55.
- 10
11 19 Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population
12 study. *Addiction (Abingdon, England)* 2014;**109**(3):491-9.
- 13
14 20 Raupach T, Brown J, Herbec A, et al. A systematic review of studies assessing the association between
15 adherence to smoking cessation medication and treatment success. *Addiction* 2014;**109**(1):35-43.
- 16
17 21 Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch
18 use and treatment efficacy: Secondary analysis of a 10 week randomized, double-blind, placebo-
19 controlled clinical trial simulating over-the-counter use in adult smokers. *Clinical therapeutics*
20 2008;**30**(10):1852-8.
- 21
22 22 Lee JH, Jones PG, Bybee K, et al. A longer course of varenicline therapy improves smoking cessation
23 rates. *Preventive cardiology* 2008;**11**(4):210-4.
- 24
25 23 U.S. Department of Commerce, Census Bureau. National Cancer Institute and Centers for Disease
26 Control and Prevention Co-sponsored Tobacco Use Supplement to the Current Population Survey (2010-
27 2011). 2012;.
- 28
29 24 U.S. Census Bureau. Current population survey: Design and methodology. *Technical Paper TP63RV,*
30 *Bureau of Labor Statistics and US Census Bureau, Washington DC* October 2006;**2014**(February 10).
- 31
32 25 Gould W. Jackknife estimation. *Stata Technical Bulletin* 1995;**4**(24).
- 33
34 26 The U.S. Census Bureau. Current Population Survey: Imputation of Unreported Data Items.
35 2014;**2014**(03/18).
- 36
37 27 Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal
38 effects. *Stata Journal* 2012;**12**(2).
- 39
40 28 Raupach T, Shahab L, Neubert K, et al. Implementing a hospital-based smoking cessation programme:
41 evidence for a learning effect. *Patient education and counseling* 2008;**70**(2):199-204.
- 42
43 29 Fu SS, Burgess D, van Ryn M, et al. Views on smoking cessation methods in ethnic minority
44 communities: a qualitative investigation. *Preventive medicine* 2007;**44**(3):235-40.
- 45
46 30 Ryan KK, Garrett-Mayer E, Alberg AJ, et al. Predictors of cessation pharmacotherapy use among black
47 and non-Hispanic white smokers. *Nicotine & tobacco research : official journal of the Society for*
48 *Research on Nicotine and Tobacco* 2011;**13**(8):646-52.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1 31 Cokkinides VE, Ward E, Jemal A, et al. Under-use of smoking-cessation treatments: results from the
2 National Health Interview Survey, 2000. *American Journal of Preventive Medicine* 2005;**28**(1):119-22.
3
- 4 32 Berg CJ, An LC, Kirch M, et al. Failure to report attempts to quit smoking. *Addictive Behaviors*
5 2010;**35**(10):900-4.
6
- 7 33 Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. *Respiratory*
8 *medicine* 2008;**102**(8):1182-92.
9
- 10 34 Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective
11 study of an Australian national sample. *Addiction* 2006;**110**:121-7.
12
- 13 35 Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction*
14 2007;**102**(5):809-14.
15
- 16 36 Pfizer Inc. Getting started with CHANTIX: Things to Remember. 2014;**2014**(March 2014).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Association between duration of use and success Effectiveness of pharmacotherapy for
smoking cessation: Findings from a national survey in the general population:
Duration of use matters**

Mohammad Siahpush, PhD
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Corresponding author:
Raees A. Shaikh, MPH
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
Email: raees.shaikh@unmc.edu | Tel: 402-559-1936 | Fax: 402-559-3773

Molly McCarthy, MPH
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Asia Sikora Kessler, PhD
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Melissa Tibbits, PhD
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Gopal K. Singh, Ph.D., M.S., M.Sc.
U.S. Department of Health & Human Services
5600 Fishers lane, Room 18-41 | Rockville, MD 20857 | USA

Word Count: ~~2582~~ **2496**

Key Words: Pharmacotherapy for Smoking Cessation, Duration of Pharmacotherapy Use,
Smoking Cessation, Assisted Cessation

Formatted: Highlight

ABSTRACT

Aim/Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the United States, controlling for nicotine dependence and sociodemographic variables.

Setting: United States

Participants:

Methods: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker one year prior to the survey (n = 8263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray, and inhaler) for smoking cessation.

Primary Outcome Measure: Successful Smoking Cessation

Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found ~~overwhelming~~ evidence ($p < 0.001$) for ~~an~~ association ($p < 0.001$) between duration of pharmacotherapy use and smoking cessation. Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than five weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioral counseling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively.

1
2
3
4
5
6
7 **Conclusion:** Pharmacotherapies for smoking cessation can be effective in the general
8
9 population if used for at least five weeks. [Results suggest that e](#)ncouraging smokers who
10
11 intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve
12
13 chances of a successful cessation.

ARTICLE SUMMARY

Strengths and limitations of the study:

- This was the first population-based study to examine the [association between the](#)
duration of use of prescription medication as well as NRT for smoking cessation ~~as a~~
~~predictor of~~ [and](#) successful smoking cessation, controlling for nicotine dependence and
sociodemographic variables.
- A strength of this study was that it used a large nationally representative sample with a
relatively high response rate.
- Our results strengthen the findings of clinical trials about the efficacy of
pharmacotherapy for smoking cessation and indicate that these aids ~~could~~ [might](#) also be
~~effective~~ [successful](#) in the general population if they are used for at least five weeks.
- [A strong possibility of reverse causation such that relapse would determine duration of](#)
[pharmacotherapy use rather than vice versa, was a major limitation of this study.](#) Recall
bias, especially related to the smokers previous quit attempts and the observational
nature of the study precluding the establishment of a causal link were between the
duration of pharmacotherapy use and successful smoking cessation, were the ~~major~~
~~other~~ [limitations.](#) ~~of this study.~~

INTRODUCTION

Clinical trials provide strong evidence that pharmacotherapy for smoking cessation including various forms of nicotine replacement therapies (NRT), [bB](#)upropion, or [vV](#)arenicline greatly increase the chances of a successful smoking cessation attempt.[1, 2] However, observational population-based studies have shown mixed results. While some have shown that pharmacotherapy increases smoking cessation rates,[3-6] others have concluded the opposite.[7-11] Yet, other population-based studies have shown no difference in cessation rates between those who use and those who do not use pharmacotherapy.[12, 13] The population-based reports that have found no favorable effect of pharmacotherapy have been criticized for not controlling for nicotine dependence,[14-16] which is a predictor of abstinence and is usually higher among smokers who choose to use pharmacotherapy for smoking cessation.[4, 14, 17, 18] Some of the analyses that have controlled for nicotine dependence have found a favorable effect of pharmacotherapy on smoking cessation[3, 4, 19] but others have not.[7]

An additional confounder that rarely is taken into account in population-based studies is duration of use of pharmacotherapy, which has been found to be associated with treatment success in clinical trials.[20-22] We know of one population-based study which examined the association of duration of use of pharmacotherapy with smoking cessation and found no association.[12] This study was conducted in the US where NRT can be purchased over the counter and medications such as [bB](#)upropion and [vV](#)arenicline can only be obtained as prescription drugs.

While clinical trials have high internal validity and can provide evidence for the efficacy of pharmacotherapy, observational population-based studies can address effectiveness of these

1
2
3
4
5
6
7 therapies under conditions that they are intended to be used.[14] Furthermore, while clinical
8 trials provide confidence in causal associations, population-based studies are strong in
9 representativeness and external validity. Thus, both are needed to advance the science of
10 smoking cessation.[19]

11
12
13
14
15 There is no literature on population-based studies that examine the association of
16 duration of NRT and prescription medication use with smoking cessation. Our aim was to use a
17 large representative sample of the general population in the United States and investigate the
18 association of the duration of use of prescription medications and NRT with smoking cessation,
19 controlling for nicotine dependence and sociodemographic variables.
20
21
22
23

24 METHODS

25 Data

26
27
28
29 We used data from the 2010-2011 Tobacco Use Supplement to the Current Population
30 Survey (TUS-CPS), sponsored by the National Cancer Institute and administered by the US
31 Census Bureau in May 2010, August 2010, and January 2011.[23] The TUS-CPS is administered
32 as a part of the CPS, which is a monthly national survey of representative households by the US
33 Census Bureau and the Bureau of Labor Statistics.[24] The TUS-CPS utilizes a multistage
34 probability sampling of individuals 15 years and older, from a sample of approximately 56,000
35 housing units, in turn selected from 792 primary sampling units. The average response rate for
36 CPS for the 3 months of surveys used in this study was 93%, whereas for the TUS it was 63%.
37
38
39
40
41
42
43
44

45 Measurement

46 *Successful smoking cessation:*

47
48
49 Individuals who reported to have smoked at least 100 cigarettes in their entire life but
50 were not smoking at all at the time of the interview [and were a daily smoker one year prior to](#)
51
52

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[the interview \("Around this time 12 months ago were you smoking everyday ...?"\)](#) were considered to have successfully quit smoking (n = 1 769). Those who reported to have quit within the last four weeks were excluded from the analysis (n = 322). Individuals who reported to have smoked at least 100 cigarettes in their entire life, were smoking every day at the time of the interview and had made a quit attempt in the past year were considered to have failed in their quit attempt (n = 7 304). Individuals who reported to have used both prescription medication and NRT for smoking cessation were excluded from the analysis (n = 488) because after subdividing this group by categories of duration of use for prescription medication and NRT, some of the subgroup sample sizes were extremely small. The total sample size for the study was 8 263 respondents, consisting of 1 379 who successfully quit smoking and 6 884 whose quit attempt was not successful.

Assisted quit attempt and duration of pharmacotherapy use:

Both daily and former smokers were asked in three separate questions to indicate whether, in their last quit attempt in the past year, they used a prescription pill called (a) Chantix or [Varenicline/varenicline](#), (b) [zZyban](#), [bBupropion](#), or [wWellbutrin](#), or (b) other prescription pills. They were also asked in three separate questions to indicate whether, in their last quit attempt [in the past year](#), they used (a) a nicotine patch, (b) nicotine gum or nicotine lozenge, or (c) nicotine nasal spray or nicotine inhaler. They were also asked to indicate how many days, weeks or months they used these prescription and/or NRT medications.

Furthermore, both daily and former smokers were asked three separate questions about use of behavioral counseling in their last quit attempt in the past year. They were asked if they used a (a) telephone helpline or quitline, (b) one-on-one counseling or (c) stop smoking clinic, class or

1
2
3
4
5
6
7 support group. Based on the questions about use of prescription medication, NRT and
8 behavioral counseling, we created the following two categorical variables:
9

10 Method of quit attempt

- 11 • Prescription medication only
- 12
- 13 • Prescription medication and behavioral counseling
- 14
- 15 • NRT only
- 16
- 17 • NRT and behavioral counseling
- 18
- 19 • Behavioral counseling only
- 20
- 21 • Unassisted
- 22
- 23
- 24

25 Duration of use of pharmacotherapy

- 26 • Prescription medication: 5+ weeks
- 27
- 28 • Prescription medication: 3-4 weeks
- 29
- 30 • Prescription medication: 1-2 weeks¹
- 31
- 32 • NRT: 5+ weeks
- 33
- 34 • NRT: 3-4 weeks
- 35
- 36 • NRT: 1-2 weeks
- 37
- 38 • Behavioral counseling only
- 39
- 40 • Unassisted
- 41
- 42
- 43

44 We categorized duration of use of pharmacotherapy based on a systematic review of
45 studies assessing adherence to smoking cessation medication.[20] In categorizing duration of
46 use, we made no distinction between whether or not the medication was combined with
47 behavioral counseling as this distinction was inconsequential in the analysis.
48
49
50

51 **Statistical analysis**

1
2
3
4
5
6
7 We used multivariable logistic regression models to compute adjusted odds ratios for
8
9 the association of the method of quit attempt and duration of use of pharmacotherapy with
10
11 successful smoking cessation. Sampling weights were taken into account in the computation of
12
13 parameter estimates. We computed *p*-values using the jackknife, which is an unbiased
14
15 estimator for a statistic and a data-dependent method to calculate standard errors.[25] All
16
17 models controlled for daily cigarette consumption (current daily consumption among daily
18
19 smokers, and daily consumption 12 months ago among former smokers), age, race/ethnicity,
20
21 education, occupation, and family income. In order to account for the missing income data, CPS
22
23 uses one of the three imputation methods, relational imputation, longitudinal edits, or hot deck
24
25 allocation. Details of these methods are described elsewhere.[26] In multivariable logistic
26
27 regression models, we omitted observations that had a missing value for any of the covariates.
28
29 This constituted 1.7% of the full sample in the analysis pertaining to the method of quit attempt
30
31 (n = 142) and 6.3% of the full sample in the analysis pertaining to duration of pharmacotherapy
32
33 use (n = 491). We used the logistic regression results to compute adjusted cessation rates by
34
35 method of quit attempt and duration of use of pharmacotherapy. These adjusted rates were
36
37 computed by fixing covariates at their means in the fitted models.[27]

38 RESULTS

39 Sample characteristics and bivariate associations

Table 1. Weighted sample characteristics and unadjusted smoking cessation rates across categories of each covariate

Variable	% in sample	% quit	p- value
Method of quit attempt			0.074
Prescription only	10.01	18.54	
Prescription plus behavioral support	1.14	23.8	
NRT only	18.26	14.32	
NRT plus behavioral support	2.54	18.98	
Behavioral only	1.36	18.59	
Unassisted	66.68	17.16	
Duration of pharmacotherapy use			<0.001
Prescription: 5+ weeks	4.9	34.38	
Prescription: 3-4 weeks	1.43	16.82	
Prescription: 1-2 weeks	1.89	15.28	
NRT: 5+ weeks	6.04	30.65	
NRT: 3-4 weeks	1.48	19.9	
NRT: 1-2 weeks	13.48	7.36	
Behavioral only	1.42	18.59	
Unassisted	69.36	17.16	
Cigarettes per day			<0.001
0-9	24.48	15.08	
10-14	30.04	12.58	
15-19	10.31	12.58	
20-29	29.23	21.83	
30+	5.93	29.59	
Sex			0.975
Female	50.12	16.99	
Male	49.88	17.02	
Age			< 0.001
18-24	11.79	15.32	
25-39	33.08	18.17	
40-54	32.33	14.49	
55+	22.8	19.77	
Race/Ethnicity			0.003
Non-Hispanic White	76.17	17.99	
Non-Hispanic Black	11.34	12.98	
Hispanic	7.39	15.73	
Other	5.09	13.15	
Education			<0.001
Less than high school	15.25	13.15	
High school diploma	73.34	16.74	
Bachelor's degree	11.41	23.91	
Occupation			<0.001
Professional	14.33	20.99	
Service	12.31	13.96	
Sales	14.5	18.45	
Farming/construction/production	17.28	13.08	
Unemployed	12.01	13.81	
Not in labor force	29.57	19.24	
Family income			<0.001
<\$25,000	36.27	13.94	
\$25,000-\$49,000	31.65	17.21	
\$50,000-\$99,000	23.86	19.63	
\$100,000+	8.23	22.17	
Full sample		17.01	

Note: Sample size for each covariate varies from 7 820 to 8 263 depending on the number of missing values for that covariate.
P-values are based on chi-square tests.

Formatted: Font: (Default) Calibri, Italic

1
2
3
4
5
6
7 Weighted sample characteristics are shown in Table 1. About 66.7% of the sample
8 reported to have made an unassisted quit attempt; 10% used only prescription medication;
9 1.1% used prescription medication plus behavioral counseling; 18.2% used only NRT; 2.5% used
10 NRT plus behavioral therapy; and 1.3% used only behavioral counseling. When broken down by
11 duration of use, while most of those who used prescription medication did so for five or more
12 weeks, the great majority of those who used NRT did so for 2 weeks or less. The reported
13 number of cigarettes smoked per day was 14 or less for about 54.5% of the sample. Age was
14 distributed with 11.8% of the sample under 25 years of age, 33% between 25-39 years, 32.3%
15 between 40-54 years, and 22.8% 55 years or older. The sample was 76% non-Hispanic white,
16 11.3% non-Hispanic Black, 7.4% Hispanic, and 5% of other race/ethnicity. About 15.2% of the
17 sample did not have a high school diploma, 73.3% had high school diploma, and 11.4% had at
18 least a bachelor's degree. The distribution of family income was skewed such that over a third
19 of the sample had an income of less than \$25 000 and less than a tenth of the sample had an
20 income of \$100 000 or greater.
21
22

23
24
25
26
27
28 Table 1 also provides smoking cessation rates across categories of each covariate,
29 indicating bivariate (unadjusted) associations between the covariates and quitting. Cessation
30 rate was 17% in the whole sample. There was very little evidence that method of quit attempt
31 was associated with cessation rate ($p < 0.074$). However, ~~there was overwhelming evidence~~
32 ~~that the~~ duration of pharmacotherapy use ~~was associated with quitting~~ ($p < 0.001$), ~~such that~~
33 ~~the use of prescription medication or NRT for 5+ weeks was associated with remarkably higher~~
34 ~~cessation rates compared to the use of these products for shorter durations, behavioral~~
35 ~~counseling or unassisted quit attempts.~~ ~~Number of cigarettes smoked per day had a~~
36 ~~curvilinear relationship with cessation such that those who smoked 0-9 cigarettes and those~~
37 ~~who smoked 20+ cigarettes per day had a higher cessation rate than others~~ ($p < 0.001$), ~~a~~ Age
38 ~~had a curvilinear relationship with cessation in that individuals in the 25-39 and 55+ age~~
39 ~~categories had notably higher cessation rates than others~~ ($p < 0.001$), ~~and~~ ~~ra~~ Race/ethnicity (p
40 ~~= 0.003~~) ~~were~~ ~~was~~ ~~all~~ associated with quitting. ~~such that Non-Hispanic Whites had the highest~~
41 ~~and non-Hispanic Blacks had the lowest cessation rates~~ ($p = 0.003$). ~~Higher~~ Higher socioeconomic
42 status as measured by education, occupation, and income was associated with a higher
43 cessation rate ($p < 0.001$ for all three indicators of socioeconomic status). Sex had no
44 association with cessation.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Adjusted results from multivariable logistic regression models

Table 2 provides adjusted odds ratios for the association of method of quit attempt with the probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence of an association between quitting method and successful cessation, the adjusted results

Formatted: Line spacing: 1.5 lines

Formatted: Left, Line spacing: 1.5 lines

Table 2. Adjusted^a odds ratios and 95% confidence intervals (CI) for the association of method of quit attempt and duration of pharmacotherapy use with the probability of successful smoking cessation

	OR (95% CI)	p-value
Method of quit attempt (n = 8 121)		
Prescription only	1.00	0.025
Prescription plus behavioral support	1.42 (0.76-2.66)	0.277
NRT only	0.78 (0.59-1.02)	0.072
NRT plus behavioral support	1.17 (0.73-1.86)	0.513
Behavioral only	1.06 (0.57-1.97)	0.844
Unassisted	1.09 (0.87-1.37)	0.464
Duration of pharmacotherapy use (n = 7 772)		
Prescription: 5+ weeks	1.00	< 0.001
Prescription: 3-4 weeks	0.42 (0.21-0.84)	0.014
Prescription: 1-2 weeks	0.38 (0.22-0.66)	0.001
NRT: 5+ weeks	0.95 (0.67-1.36)	0.786
NRT: 3-4 weeks	0.53 (0.29-0.97)	0.040
NRT: 1-2 weeks	0.16 (0.11-0.24)	<0.001
Behavioral only	0.47 (0.25-0.90)	0.022
Unassisted	0.48 (0.37-0.64)	<0.001

^a Adjusted for the effect of number of cigarettes smoked per day, sex, age, race/ethnicity, education, occupation, and family income.

Figure 1 here.....

Formatted: Font: Not Bold

Table 2 provides adjusted odds ratios for the association of method of quit attempt with the probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence of an association between quitting method and successful cessation, the adjusted results

Formatted: Indent: First line: 0"

revealed some evidence of an association ($p = 0.025$). The highest cessation rate was among those who used prescription medication and behavioral counseling (20.4%) followed by those who used NRT and behavioral counseling (17.4%), attempted to quit unassisted (16.4%), used

1
2
3
4
5
6
7 behavioral counseling only (16.1%), and those who used prescription medication only (15.3%).
8 The lowest cessation rate was among those who only used NRT as a quitting method (12.3%).
9

10
11 Figure 2 here.....

Formatted: Font: Not Bold

12
13
14 Table 2 also provides adjusted odds ratios for the association of duration of
15 pharmacotherapy use with the probability of smoking cessation. Figure 2 shows the adjusted
16 cessation rates for various durations of pharmacotherapy use. Consistent with the unadjusted
17 results in Table 1, the adjusted results [in Table 2 also](#) provide **strong** evidence ($p < 0.001$) of an
18 association between duration of pharmacotherapy use and successful cessation. [As shown in](#)
19 [Figure 2, cessation rates were highest among those who used prescription medication for 5+](#)
20 [weeks \(28.8%\) and those who used NRT for 5+ weeks \(27.8%\) had higher cessation rates,](#)
21 [28.8% and 27.8% respectively, than others.](#) Cessation rates for those who used prescription
22 medication or NRT for less than five weeks varied from 6.2% to 14.5%. Cessation rates for those
23 who used only behavioral counseling and those who attempted to quit smoking unassisted
24 were 16.1% and 16.4%, respectively.
25

26
27 The results pertaining to the association of other covariates with successful cessation
28 were very similar in the multivariable regression models for method of quit attempt and
29 duration of pharmacotherapy use. These results were consistent with bivariate associations
30 reported above, except for the fact that there was very little evidence for an association of
31 race/ethnicity and smoking cessation in multivariable analyses.
32

33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

DISCUSSION

This is the first population-based study to examine the [association of successful smoking](#)
[cessation and](#) duration of use of prescription medication as well as NRT for smoking cessation
[as a predictor of successful smoking cessation.](#) We found that using pharmacotherapy for five
weeks or longer is associated with a **remarkably** higher probability of cessation compared to
using pharmacotherapy for shorter durations, only using behavioral counseling or trying to quit
unassisted.

Our findings are consistent with the results of a study of a hospital-based cessation
program where participants who used NRT for 5 weeks or longer were found to have a higher

1
2
3
4
5
6
7 cessation rate at 6-month follow-up.[28] However, our findings are not consistent with those of
8 a population-based study which did not find any evidence that using NRT for more than 6
9 weeks versus not using NRT at all was associated with smoking cessation.[12] In that study, the
10 survey response rate was low, the sample size was small and prescription medications were not
11 examined. These factors could explain the discrepant findings.
12

13
14 While we found that smokers who used pharmacotherapy for at least 5 weeks have a far
15 more favorable outcome than others, only 11% of the sample was in this group and notably
16 about 70% of the sample did not use any pharmacotherapy for smoking cessation. Previous
17 research indicates that barriers to the use of these cessation aids include concerns with their
18 addictiveness, cost and side effects, as well as the belief that a treatment of any kind is not
19 needed to quit smoking.[29-31]
20

21
22 A major weakness/limitation of the study is that there is a strong possibility of reverse
23 causation such that relapse would determine duration of pharmacotherapy use rather than vice
24 versa.[35] Smokers who use varenicline to quit smoking are asked to completely stop smoking
25 one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a
26 short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit
27 attempt would cause a short duration of pharmacotherapy use instead of the reverse.
28 Furthermore, because of its observational nature, our study cannot establish a causal link
29 between the duration of pharmacotherapy use and successful smoking cessation. While our
30 analyses controlled for several important predictors of cessation including daily cigarette
31 consumption, age, race, education, occupation, and income, it is possible that there might be
32 residual confounding related to variables such as depression, anxiety, alcohol use, and financial
33 stress.[33, 34] Such confounding would further weaken the ability of the study to imply
34 causation.
35

36
37 Another weakness of the study relates to the fact that smokers forget many quit
38 attempts [7, 32] and they are more prone to recall attempts that used pharmacotherapy than
39 those that did not.[14, 17] Such recall bias can underestimate the success rate of attempts at
40 quitting with the aid of pharmacotherapy.[17] Another limitation of the study is that because of
41 its observational nature, our study cannot establish a causal link between the duration of
42 pharmacotherapy use and successful smoking cessation. While our analyses controlled for
43 several important predictors of cessation including daily cigarette consumption, age, race,
44
45
46
47
48
49
50
51
52
53

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

education, occupation, and income, it is possible that there is residual confounding related to variables such as depression, anxiety, alcohol use, and financial stress.[33, 34] Such confounding would further weaken the ability of the study to imply causation. Moreover, there is a possibility of reverse causation such that relapse would determine duration of pharmacotherapy use rather than vice versa.[35] Smokers who use Varenicline to quit smoking are asked to completely stop smoking one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit attempt would cause a short duration of pharmacotherapy use instead of the reverse.

A strength of this study was that it used a large nationally representative sample with a relatively high response rate. This was the first time that questions about the duration of pharmacotherapy use were included in the TUS-CPS. We know of no other national data on the general population that provide information on this variable. Many population-based studies of pharmacotherapies for smoking cessation have found these aids to be ineffective. It is likely that if these studies were able to account for duration of use, their findings would have been different. However, data on duration of use is not routinely collected and it would require a large sample size to provide a reliable estimate of the effect of using these medications for duration of a few weeks. Nonetheless, it would likely be an important area for further research to establish the relationship between duration of use of pharmacotherapy and successful quitting in the general population.

Our results strengthen the findings of clinical trials about the efficacy of pharmacotherapy for smoking cessation and indicate that these aids can might also be effective successful in the general population if they are used for at least five weeks. Smokers who intend to quit should be encouraged to use pharmacotherapy and adhere to their recommended duration of use.

CONTRIBUTORSHIP STATEMENT

We assure that all authors included on a paper fulfill the criteria of authorship. All have contributed in the conception and design, analysis and interpretation of data, drafting of the article and revising it critically for important intellectual content, and final approval of the version to be published. In addition we also assure that there is no one else who fulfills the criteria but has not been included as an author. Dr. Mohammad Siahpush was instrumental in conceptualization of research study, data analysis, and writing of the initial draft of the manuscript. Raees Shaikh and Molly McCarthy contributed in the development of study, data analysis, and preparation of the results section. They also helped with writing the manuscript and editing it for final submission. Dr. Asia Sikora helped with literature review, provided inputs for the materials and method section, and contributed to writing and editing the manuscript. Dr. Melissa Tibbits was involved with literature review and data analysis and provided her inputs to the entire manuscript. Dr. Gopal Singh was involved with formulation of research study and helped in the data analysis and contributed in the writing and editing of the final manuscript.

DETAILS OF FUNDING

This work did not require or receive funding.

CONFLICT OF INTEREST STATEMENT

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) declare that no support was received from any organization for the submitted work and that there was no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, neither did we have other relationships or activities that could appear to have influenced the submitted work.

ETHICAL APPROVAL STATEMENT

No ethical approval was required for this work.

DATA SHARING STATEMENT

No additional data used or available.

FIGURE LEGENDS

Figure1: Adjusted Cessation Rate by Method of Quit Attempt

Figure2: Adjusted Cessation Rate by Duration of Pharmacotherapy Use

REFERENCES

- 1 Raupach T, van Schayck C,P. Pharmacotherapy for smoking cessation: current advances and research topics. *CNS Drugs* 2011;**25**(5):371-82.
- 2 Cahill K, Stevens S, Lancaster T. Pharmacological Treatments for Smoking Cessation. *JAMA* 2014;**311**(2):193-4.
- 3 Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2013;**108**(1):193-202.
- 4 West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. *Thorax* 2007;**62**(11):998-1002.
- 5 Cummings KM, Fix B, Celestino P, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. *Journal of Public Health Management and Practice* 2006;**12**(1):37-43.
- 6 Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. *Lancet* 2005;**365**:1849-54.
- 7 Shiffman S, Brockwell SE, Pillitteri JL, et al. Use of smoking-cessation treatments in the United States. *American Journal of Preventive Medicine* 2008;**34**(2):102-11.
- 8 Alberg AJ, Patnaik JL, May JW, et al. Nicotine replacement therapy use among a cohort of smokers. *Journal of addictive diseases* 2005;**24**(1):101-13.
- 9 Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. *American Journal of Public Health* 2007;**97**(8):1503-9.
- 10 Hagimoto A, Nakamura M, Morita T, et al. Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. *Addiction* 2010;**105**(1):164-73.
- 11 Yang J, Hammond D, Driezen P, et al. The use of cessation assistance among smokers from China: Findings from the ITC China Survey. *BMC public health* 2011;**11**(1):75.
- 12 Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. *Tobacco control* 2013;**22**(1):32-7.
- 13 Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *Jama* 2002;**288**(10):1260-4.
- 14 Hughes JR, Peters EN, Naud S. Effectiveness of over-the-counter nicotine replacement therapy: a qualitative review of nonrandomized trials. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2011;**13**(7):512-22.
- 15 Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. *Drug and Alcohol Review* 2008;**27**(5):529-47.

- 1
2
3
4
5
6
7 16 Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the
8 succeeding. *Tobacco control* 2009;**18**(1):43-6.
9
10 17 Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may
11 underestimate the effectiveness of stop-smoking medications. *Nicotine & Tobacco Research*
12 2012;**14**(12):1483-7.
13
14 18 Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy.
15 *Tobacco control* 2005;**14**(5):346-55.
16
17 19 Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population
18 study. *Addiction (Abingdon, England)* 2014;**109**(3):491-9.
19
20 20 Raupach T, Brown J, Herbec A, et al. A systematic review of studies assessing the association between
21 adherence to smoking cessation medication and treatment success. *Addiction* 2014;**109**(1):35-43.
22
23 21 Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch
24 use and treatment efficacy: Secondary analysis of a 10 week randomized, double-blind, placebo-
25 controlled clinical trial simulating over-the-counter use in adult smokers. *Clinical therapeutics*
26 2008;**30**(10):1852-8.
27
28 22 Lee JH, Jones PG, Bybee K, et al. A longer course of varenicline therapy improves smoking cessation
29 rates. *Preventive cardiology* 2008;**11**(4):210-4.
30
31 23 U.S. Department of Commerce, Census Bureau. National Cancer Institute and Centers for Disease
32 Control and Prevention Co-sponsored Tobacco Use Supplement to the Current Population Survey (2010-
33 2011). 2012;.
34
35 24 U.S. Census Bureau. Current population survey: Design and methodology. *Technical Paper TP63RV,*
36 *Bureau of Labor Statistics and US Census Bureau, Washington DC* October 2006;**2014**(February 10).
37
38 25 Gould W. Jackknife estimation. *Stata Technical Bulletin* 1995;**4**(24).
39
40 26 The U.S. Census Bureau. Current Population Survey: Imputation of Unreported Data Items.
41 2014;**2014**(03/18).
42
43 27 Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal
44 effects. *Stata Journal* 2012;**12**(2).
45
46 28 Raupach T, Shahab L, Neubert K, et al. Implementing a hospital-based smoking cessation programme:
47 evidence for a learning effect. *Patient education and counseling* 2008;**70**(2):199-204.
48
49 29 Fu SS, Burgess D, van Ryn M, et al. Views on smoking cessation methods in ethnic minority
50 communities: a qualitative investigation. *Preventive medicine* 2007;**44**(3):235-40.
51
52 30 Ryan KK, Garrett-Mayer E, Alberg AJ, et al. Predictors of cessation pharmacotherapy use among black
53 and non-Hispanic white smokers. *Nicotine & tobacco research : official journal of the Society for*
54 *Research on Nicotine and Tobacco* 2011;**13**(8):646-52.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

31 Cokkinides VE, Ward E, Jemal A, et al. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. *American Journal of Preventive Medicine* 2005;**28**(1):119-22.

32 Berg CJ, An LC, Kirch M, et al. Failure to report attempts to quit smoking. *Addictive Behaviors* 2010;**35**(10):900-4.

33 Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. *Respiratory medicine* 2008;**102**(8):1182-92.

34 Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective study of an Australian national sample. *Addiction* 2006;**110**:121-7.

35 Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction* 2007;**102**(5):809-14.

36 Pfizer Inc. Getting started with CHANTIX: Things to Remember. 2014;**2014**(March 2014).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure1- Adjusted Cessation Rate by Method of Quit Attempt
105x76mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure2- Adjusted Cessation Rate by Duration of Pharmacotherapy Use
105x76mm (300 x 300 DPI)

View only

STROBE Statement Checklist

	Checklist
Title and abstract	Yes
Introduction	
Background/rationale	Yes
Objectives/Aims	Yes
Methods	
Data sources	Yes
Measurement	Yes
Statistical methods	Yes
Results	
Descriptive data	Yes
Main results	Yes
Discussion	
Key results	Yes
Interpretation	Yes
Generalizability/Strengths	Yes
Limitations	Yes
Other information	
Funding	Yes
Competing Interest Statement:	Yes
Ethical Approval Statement	Yes
Contributorship Statement	Yes

BMJ Open

Association between duration of use of pharmacotherapy and smoking cessation: Findings from a national survey

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006229.R2
Article Type:	Research
Date Submitted by the Author:	16-Dec-2014
Complete List of Authors:	Siahpush, Mohammad; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Shaikh, Raees; College of Public Health - University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health McCarthy, Molly; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Sikora, Asia; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Tibbits, Melissa; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health; University of Nebraska Medical Center, Department of Health Promotion, Social and Behavioral Health Singh, Gopal; Health Resources and Services Administration, Maternal and Child Health Bureau, US Department of Health and Human Services
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Addiction, Public health
Keywords:	PREVENTIVE MEDICINE, PUBLIC HEALTH, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts

1 **Association between duration of use of pharmacotherapy and smoking cessation: Findings**
2 **from a national survey**
3
4

5 Mohammad Siahpush, PhD
6

7 Department of Health Promotion, Social and Behavioral Health
8 College of Public Health | University of Nebraska Medical Center
9 984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
10

11
12 Corresponding author:

13 Raees A. Shaikh, MPH
14

15 Department of Health Promotion, Social and Behavioral Health
16 College of Public Health | University of Nebraska Medical Center
17 984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
18 Email: raees.shaikh@unmc.edu | Tel: 402-559-1936 | Fax: 402-559-3773
19
20
21

22 Molly McCarthy, MPH
23

24 Department of Health Promotion, Social and Behavioral Health
25 College of Public Health | University of Nebraska Medical Center
26 984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
27
28

29 Asia Sikora Kessler, PhD
30

31 Department of Health Promotion, Social and Behavioral Health
32 College of Public Health | University of Nebraska Medical Center
33 984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
34
35

36 Melissa Tibbits, PhD
37

38 Department of Health Promotion, Social and Behavioral Health
39 College of Public Health | University of Nebraska Medical Center
40 984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
41
42
43

44 Gopal K. Singh, Ph.D., M.S., M.Sc.
45

46 U.S. Department of Health & Human Services
47 5600 Fishers lane, Room 18-41 | Rockville, MD 20857 | USA
48
49

50 **Word Count**2496

51 **Key Words:** Pharmacotherapy for Smoking Cessation, Duration of Pharmacotherapy Use,
52 Smoking Cessation, Assisted Cessation
53
54
55
56
57
58
59
60

ABSTRACT

Objective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the United States, controlling for nicotine dependence and sociodemographic variables.

Setting: United States

Participants: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker one year prior to the survey (n = 8 263). Respondents were asked about duration of use of prescription medication (varenicline, bupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray, and inhaler) for smoking cessation.

Primary Outcome Measure: Successful Smoking Cessation. Individuals who reported to have smoked at least 100 cigarettes in their lifetime but were not smoking at all at the time of the interview and were a daily smoker one year prior to the interview were considered to have successfully quit smoking.

Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found evidence for an association between duration of pharmacotherapy use and smoking cessation ($p < 0.001$). Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for less than five weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used only behavioral counseling and those who attempted to quit smoking unassisted were 16.1% and 16.4%, respectively.

Conclusion: Use of pharmacotherapy for at least five weeks is associated with increased likelihood of successful smoking cessation. Results suggest that encouraging smokers who intend to quit to use pharmacotherapy and to adhere to treatment duration can help improve chances of a successful cessation.

ARTICLE SUMMARY

Strengths and limitations of the study:

- This was the first population-based study to examine the association between the duration of use of prescription medication as well as NRT for smoking cessation and successful smoking cessation, controlling for nicotine dependence and sociodemographic variables.
- A strength of this study was that it used a large nationally representative sample with a relatively high response rate.
- Our results strengthen the findings of clinical trials about the efficacy of pharmacotherapy for smoking cessation and indicate that these aids might also be successful in the general population if they are used for at least five weeks.
- A strong possibility of reverse causation such that relapse would determine duration of pharmacotherapy use rather than vice versa, was a major limitation of this study. Recall bias, especially related to the smokers previous quit attempts and the observational nature of the study precluding the establishment of a causal link were between the duration of pharmacotherapy use and successful smoking cessation, were the other limitations.

INTRODUCTION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Clinical trials provide strong evidence that pharmacotherapy for smoking cessation including various forms of nicotine replacement therapies (NRT), bupropion, or varenicline greatly increase the chances of a successful smoking cessation attempt.[1, 2] However, observational population-based studies have shown mixed results. While some have shown that pharmacotherapy increases smoking cessation rates,[3-6] others have concluded the opposite.[7-11] Yet, other population-based studies have shown no difference in cessation rates between those who use and those who do not use pharmacotherapy.[12, 13] The population-based reports that have found no favorable effect of pharmacotherapy have been criticized for not controlling for nicotine dependence,[14-16] which is a predictor of abstinence and is usually higher among smokers who choose to use pharmacotherapy for smoking cessation.[4, 14, 17, 18] Some of the analyses that have controlled for nicotine dependence have found a favorable effect of pharmacotherapy on smoking cessation[3, 4, 19] but others have not.[7]

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
An additional confounder that rarely is taken into account in population-based studies is duration of use of pharmacotherapy, which has been found to be associated with treatment success in clinical trials.[20-22] We know of one population-based study which examined the association of duration of use of pharmacotherapy with smoking cessation and found no association.[12] This study was conducted in the US where NRT can be purchased over the counter and medications such as bupropion and varenicline can only be obtained as prescription drugs.

54
55
56
57
58
59
60
While clinical trials have high internal validity and can provide evidence for the efficacy of pharmacotherapy, observational population-based studies can address effectiveness of these

1 therapies under conditions that they are intended to be used.[14] Furthermore, while clinical
2
3 trials provide confidence in causal associations, population-based studies are strong in
4
5 representativeness and external validity. Thus, both are needed to advance the science of
6
7 smoking cessation.[19]
8
9

10
11 There is no literature on population-based studies that examine the association of
12
13 duration of NRT and prescription medication use with smoking cessation. Our aim was to use a
14
15 large representative sample of the general population in the United States and investigate the
16
17 association of the duration of use of prescription medications and NRT with smoking cessation,
18
19 controlling for nicotine dependence and sociodemographic variables.
20
21
22

23 METHODS

24 Data

25
26 We used data from the 2010-2011 Tobacco Use Supplement to the Current Population
27
28 Survey (TUS-CPS), sponsored by the National Cancer Institute and administered by the US
29
30 Census Bureau in May 2010, August 2010, and January 2011.[23] The TUS-CPS is administered
31
32 as a part of the CPS, which is a monthly national survey of representative households by the US
33
34 Census Bureau and the Bureau of Labor Statistics.[24] The TUS-CPS utilizes a multistage
35
36 probability sampling of individuals 15 years and older, from a sample of approximately 56,000
37
38 housing units, in turn selected from 792 primary sampling units. The average response rate for
39
40 CPS for the 3 months of surveys used in this study was 93%, whereas for the TUS it was 63%.
41
42
43
44
45
46
47

48 Measurement

49 *Successful smoking cessation:*

50
51
52 Individuals who reported to have smoked at least 100 cigarettes in their entire life but
53
54 were not smoking at all at the time of the interview and were a daily smoker one year prior to
55
56
57
58
59
60

1 the interview (“Around this time 12 months ago were you smoking everyday ...?”) were
2
3 considered to have successfully quit smoking (n = 1 769). Those who reported to have quit
4
5 within the last four weeks were excluded from the analysis (n = 322). Individuals who reported
6
7 within the last four weeks were excluded from the analysis (n = 322). Individuals who reported
8
9 to have smoked at least 100 cigarettes in their entire life, were smoking every day at the time
10
11 of the interview and had made a quit attempt in the past year were considered to have failed in
12
13 their quit attempt (n = 7 304). Individuals who reported to have used both prescription
14
15 medication and NRT for smoking cessation were excluded from the analysis (n = 488) because
16
17 after subdividing this group by categories of duration of use for prescription medication and
18
19 NRT, some of the subgroup sample sizes were extremely small. The total sample size for the
20
21 study was 8 263 respondents, consisting of 1 379 who successfully quit smoking and 6 884
22
23 whose quit attempt was not successful.
24
25
26
27

28 *Assisted quit attempt and duration of pharmacotherapy use:*
29

30
31 Both daily and former smokers were asked in three separate questions to indicate
32
33 whether, in their last quit attempt in the past year, they used a prescription pill called (a)
34
35 Chantix or varenicline, (b) zyban, bupropion, or wellbutrin, or (b) other prescription pills. They
36
37 were also asked in three separate questions to indicate whether, in their last quit attempt in
38
39 the past year, they used (a) a nicotine patch, (b) nicotine gum or nicotine lozenge, or (c)
40
41 nicotine nasal spray or nicotine inhaler. They were also asked to indicate how many days,
42
43 weeks or months they used these prescription and/or NRT medications. Furthermore, both
44
45 daily and former smokers were asked three separate questions about use of behavioral
46
47 counseling in their last quit attempt in the past year. They were asked if they used a (a)
48
49 telephone helpline or quitline, (b) one-on-one counseling or (c) stop smoking clinic, class or
50
51
52
53
54
55
56
57
58
59
60

1 support group. Based on the questions about use of prescription medication, NRT and
2
3 behavioral counseling, we created the following two categorical variables:
4

5
6 Method of quit attempt
7

- 8 • Prescription medication only
- 9
- 10 • Prescription medication and behavioral counseling
- 11
- 12 • NRT only
- 13
- 14 • NRT and behavioral counseling
- 15
- 16 • Behavioral counseling only
- 17
- 18 • Unassisted
- 19
- 20
- 21
- 22
- 23

24 Duration of use of pharmacotherapy
25

- 26 • Prescription medication: 5+ weeks
- 27
- 28 • Prescription medication: 3-4 weeks
- 29
- 30 • Prescription medication: 1-2 weeks¹
- 31
- 32 • NRT: 5+ weeks
- 33
- 34 • NRT: 3-4 weeks
- 35
- 36 • NRT: 1-2 weeks
- 37
- 38 • Behavioral counseling only
- 39
- 40 • Unassisted
- 41
- 42
- 43
- 44
- 45
- 46

47 We categorized duration of use of pharmacotherapy based on a systematic review of
48 studies assessing adherence to smoking cessation medication.[20] In categorizing duration of
49 use, we made no distinction between whether or not the medication was combined with
50 behavioral counseling as this distinction was inconsequential in the analysis.
51
52
53
54
55

56
57 **Statistical analysis**
58
59
60

1 We used multivariable logistic regression models to compute adjusted odds ratios for
2
3 the association of the method of quit attempt and duration of use of pharmacotherapy with
4
5 successful smoking cessation. Sampling weights were taken into account in the computation of
6
7 parameter estimates. We computed p -values using the jackknife, which is an unbiased
8
9 estimator for a statistic and a data-dependent method to calculate standard errors.[25] All
10
11 models controlled for daily cigarette consumption (current daily consumption among daily
12
13 smokers, and daily consumption 12 months ago among former smokers), age, race/ethnicity,
14
15 education, occupation, and family income. In order to account for the missing income data, CPS
16
17 uses one of the three imputation methods, relational imputation, longitudinal edits, or hot deck
18
19 allocation. Details of these methods are described elsewhere.[26] In multivariable logistic
20
21 regression models, we omitted observations that had a missing value for any of the covariates.
22
23 This constituted 1.7% of the full sample in the analysis pertaining to the method of quit attempt
24
25 (n = 142) and 6.3% of the full sample in the analysis pertaining to duration of pharmacotherapy
26
27 use (n = 491). We used the logistic regression results to compute adjusted cessation rates by
28
29 method of quit attempt and duration of use of pharmacotherapy. These adjusted rates were
30
31 computed by fixing covariates at their means in the fitted models.[27]
32
33
34
35
36
37
38
39
40

41 RESULTS

42 Sample characteristics and bivariate associations

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Weighted sample characteristics and unadjusted smoking cessation rates across categories of each covariate

Variable	% in sample	% quit	p- value
Method of quit attempt			0.074
Prescription only	10.01	18.54	
Prescription plus behavioral support	1.14	23.8	
NRT only	18.26	14.32	
NRT plus behavioral support	2.54	18.98	
Behavioral only	1.36	18.59	
Unassisted	66.68	17.16	
Duration of pharmacotherapy use			<0.001
Prescription: 5+ weeks	4.9	34.38	
Prescription: 3-4 weeks	1.43	16.82	
Prescription: 1-2 weeks	1.89	15.28	
NRT: 5+ weeks	6.04	30.65	
NRT: 3-4 weeks	1.48	19.9	
NRT: 1-2 weeks	13.48	7.36	
Behavioral only	1.42	18.59	
Unassisted	69.36	17.16	
Cigarettes per day			<0.001
0-9	24.48	15.08	
10-14	30.04	12.58	
15-19	10.31	12.58	
20-29	29.23	21.83	
30+	5.93	29.59	
Sex			0.975
Female	50.12	16.99	
Male	49.88	17.02	
Age			< 0.001
18-24	11.79	15.32	
25-39	33.08	18.17	
40-54	32.33	14.49	
55+	22.8	19.77	
Race/Ethnicity			0.003
Non-Hispanic White	76.17	17.99	
Non-Hispanic Black	11.34	12.98	
Hispanic	7.39	15.73	
Other	5.09	13.15	
Education			<0.001
Less than high school	15.25	13.15	
High school diploma	73.34	16.74	
Bachelor's degree	11.41	23.91	
Occupation			<0.001
Professional	14.33	20.99	
Service	12.31	13.96	
Sales	14.5	18.45	
Farming/construction/production	17.28	13.08	
Unemployed	12.01	13.81	
Not in labor force	29.57	19.24	
Family income			<0.001
<\$25,000	36.27	13.94	
\$25,000-\$49,000	31.65	17.21	
\$50,000-\$99,000	23.86	19.63	
\$100,000+	8.23	22.17	
Full sample		17.01	

Note: Sample size for each covariate varies from 7 820 to 8 263 depending on the number of missing values for that covariate. P-values are based on chi-square tests.

1 Weighted sample characteristics are shown in Table 1. About 66.7% of the sample
2 reported to have made an unassisted quit attempt; 10% used only prescription medication;
3 1.1% used prescription medication plus behavioral counseling; 18.2% used only NRT; 2.5% used
4 NRT plus behavioral therapy; and 1.3% used only behavioral counseling. When broken down by
5 duration of use, while most of those who used prescription medication did so for five or more
6 weeks, the great majority of those who used NRT did so for 2 weeks or less. The reported
7 number of cigarettes smoked per day was 14 or less for about 54.5% of the sample. Age was
8 distributed with 11.8% of the sample under 25 years of age, 33% between 25-39 years, 32.3%
9 between 40-54 years, and 22.8% 55 years or older. The sample was 76% non-Hispanic white,
10 11.3% non-Hispanic Black, 7.4% Hispanic, and 5% of other race/ethnicity. About 15.2% of the
11 sample did not have a high school diploma, 73.3% had high school diploma, and 11.4% had at
12 least a bachelor's degree. The distribution of family income was skewed such that over a third
13 of the sample had an income of less than \$25 000 and less than a tenth of the sample had an
14 income of \$100 000 or greater.

15
16
17
18
19
20
21
22
23
24
25
26
27 Table 1 also provides smoking cessation rates across categories of each covariate,
28 indicating bivariate (unadjusted) associations between the covariates and quitting. Cessation
29 rate was 17% in the whole sample. There was very little evidence that method of quit attempt
30 was associated with cessation rate ($p < 0.074$). However, the duration of pharmacotherapy use
31 ($p < 0.001$), number of cigarettes smoked per day ($p < 0.001$), age ($p < 0.001$), and
32 race/ethnicity ($p = 0.003$) were all associated with quitting. Higher socioeconomic status as
33 measured by education, occupation, and income was associated with a higher cessation rate (p
34 < 0.001 for all three indicators of socioeconomic status). Sex had no association with cessation.
35
36
37
38
39
40
41
42
43

44 **Adjusted results from multivariable logistic regression models**

45
46 Table 2 provides adjusted odds ratios for the association of method of quit attempt with the
47 probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various
48 quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence
49 of an association between quitting method and successful cessation, the adjusted results
50
51
52
53
54
55
56
57
58
59
60

Table 2. Adjusted^a odds ratios and 95% confidence intervals (CI) for the association of method of quit attempt and duration of pharmacotherapy use with the probability of successful smoking cessation

	OR (95% CI)	<i>p</i> -value
Method of quit attempt (n = 8 121)		0.025
Prescription only	1.00	
Prescription plus behavioral support	1.42 (0.76-2.66)	
NRT only	0.78 (0.59-1.02)	
NRT plus behavioral support	1.17 (0.73-1.86)	
Behavioral only	1.06 (0.57-1.97)	
Unassisted	1.09 (0.87-1.37)	
Duration of pharmacotherapy use (n = 7 772)		< 0.001
Prescription: 5+ weeks	1.00	
Prescription: 3-4 weeks	0.42 (0.21-0.84)	
Prescription: 1-2 weeks	0.38 (0.22-0.66)	
NRT: 5+ weeks	0.95 (0.67-1.36)	
NRT: 3-4 weeks	0.53 (0.29-0.97)	
NRT: 1-2 weeks	0.16 (0.11-0.24)	
Behavioral only	0.47 (0.25-0.90)	
Unassisted	0.48 (0.37-0.64)	

^a Adjusted for the effect of number of cigarettes smoked per day, sex, age, race/ethnicity, education, occupation, and family income.

Figure 1 here.....

revealed some evidence of an association ($p = 0.025$). The highest cessation rate was among those who used prescription medication and behavioral counseling (20.4%) followed by those who used NRT and behavioral counseling (17.4%), attempted to quit unassisted (16.4%), used behavioral counseling only (16.1%), and those who used prescription medication only (15.3%). The lowest cessation rate was among those who only used NRT as a quitting method (12.3%).

Figure 2 here.....

Table 2 also provides adjusted odds ratios for the association of duration of pharmacotherapy use with the probability of smoking cessation. Figure 2 shows the adjusted cessation rates for various durations of pharmacotherapy use. Consistent with the unadjusted results in Table 1, the adjusted results in Table 2 also provide evidence ($p < 0.001$) of an association between duration of pharmacotherapy use and successful cessation. As shown in Figure 2, cessation rates were highest among those who used prescription medication for 5+ weeks (28.8%) and those who used NRT for 5+ weeks (27.8%). Cessation rates for those who used prescription medication or NRT for less than five weeks varied from 6.2% to 14.5%.

1 Cessation rates for those who used only behavioral counseling and those who attempted to
2 quit smoking unassisted were 16.1% and 16.4%, respectively.
3

4 The results pertaining to the association of other covariates with successful cessation
5 were very similar in the multivariable regression models for method of quit attempt and
6 duration of pharmacotherapy use. These results were consistent with bivariate associations
7 reported above, except for the fact that there was very little evidence for an association of
8 race/ethnicity and smoking cessation in multivariable analyses.
9
10
11
12
13

14 DISCUSSION

15 This is the first population-based study to examine the association of successful smoking
16 cessation and duration of use of prescription medication as well as NRT for smoking cessation.
17 We found that using pharmacotherapy for five weeks or longer is associated with a higher
18 probability of cessation compared to using pharmacotherapy for shorter durations, only using
19 behavioral counseling or trying to quit unassisted.
20
21
22
23
24
25
26
27

28 Our findings are consistent with the results of a study of a hospital-based cessation
29 program where participants who used NRT for 5 weeks or longer were found to have a higher
30 cessation rate at 6-month follow-up.[28] However, our findings are not consistent with those of
31 a population-based study which did not find any evidence that using NRT for more than 6
32 weeks versus not using NRT at all was associated with smoking cessation.[12] In that study, the
33 survey response rate was low, the sample size was small and prescription medications were not
34 examined. These factors could explain the discrepant findings.
35
36
37
38
39
40

41 While we found that smokers who used pharmacotherapy for at least 5 weeks have a far
42 more favorable outcome than others, only 11% of the sample was in this group and notably
43 about 70% of the sample did not use any pharmacotherapy for smoking cessation. Previous
44 research indicates that barriers to the use of these cessation aids include concerns with their
45 addictiveness, cost and side effects, as well as the belief that a treatment of any kind is not
46 needed to quit smoking.[29-31]
47
48
49
50
51

52 A major limitation of the study is that there is a strong possibility of reverse causation
53 such that relapse would determine duration of pharmacotherapy use rather than vice
54 versa.[35] Smokers who use varenicline to quit smoking are asked to completely stop smoking
55 one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a
56
57
58
59
60

1 short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit
2 attempt would cause a short duration of pharmacotherapy use instead of the reverse.
3
4 Furthermore, because of its observational nature, our study cannot establish a causal link
5 between the duration of pharmacotherapy use and successful smoking cessation. While our
6 analyses controlled for several important predictors of cessation including daily cigarette
7 consumption, age, race, education, occupation, and income, it is possible that there might be
8 residual confounding related to variables such as depression, anxiety, alcohol use, and financial
9 stress.[33, 34] Such confounding would further weaken the ability of the study to imply
10 causation.
11
12

13
14
15
16
17
18 Another weakness of the study relates to the fact that smokers forget many quit
19 attempts [7, 32] and they are more prone to recall attempts that used pharmacotherapy than
20 those that did not.[14, 17] Such recall bias can underestimate the success rate of attempts at
21 quitting with the aid of pharmacotherapy.[17]
22
23

24
25 A strength of this study was that it used a large nationally representative sample with a
26 relatively high response rate. This was the first time that questions about the duration of
27 pharmacotherapy use were included in the TUS-CPS. We know of no other national data on the
28 general population that provide information on this variable. Many population-based studies of
29 pharmacotherapies for smoking cessation have found these aids to be ineffective. It is likely
30 that if these studies were able to account for duration of use, their findings would have been
31 different. However, data on duration of use is not routinely collected and it would require a
32 large sample size to provide a reliable estimate of the effect of using these medications for
33 duration of a few weeks. Nonetheless, it would likely be an important area for further research
34 to establish the relationship between duration of use of pharmacotherapy and successful
35 quitting in the general population.
36
37
38
39
40
41
42
43
44
45

46 Our results strengthen the findings of clinical trials about the efficacy of
47 pharmacotherapy for smoking cessation and indicate that these aids might also be successful in
48 the general population if they are used for at least five weeks.
49
50
51
52
53
54
55
56
57
58
59
60

CONTRIBUTORSHIP STATEMENT

We assure that all authors included on a paper fulfill the criteria of authorship. All have contributed in the conception and design, analysis and interpretation of data, drafting of the article and revising it critically for important intellectual content, and final approval of the version to be published. In addition we also assure that there is no one else who fulfills the criteria but has not been included as an author. Dr. Mohammad Siahpush was instrumental in conceptualization of research study, data analysis, and writing of the initial draft of the manuscript. Raees Shaikh and Molly McCarthy contributed in the development of study, data analysis, and preparation of the results section. They also helped with writing the manuscript and editing it for final submission. Dr. Asia Sikora helped with literature review, provided inputs for the materials and method section, and contributed to writing and editing the manuscript. Dr. Melissa Tibbits was involved with literature review and data analysis and provided her inputs to the entire manuscript. Dr. Gopal Singh was involved with formulation of research study and helped in the data analysis and contributed in the writing and editing of the final manuscript.

DETAILS OF FUNDING

This work did not require or receive funding.

CONFLICT OF INTEREST STATEMENT

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) declare that no support was received from any organization for the submitted work and that there was no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, neither did we have other relationships or activities that could appear to have influenced the submitted work. No competing interests to declare.

ETHICAL APPROVAL STATEMENT

No ethical approval was required for this work.

DATA SHARING STATEMENT

No additional data used or available.

FIGURE LEGENDS

Figure1: Adjusted Cessation Rate by Method of Quit Attempt

Figure2: Adjusted Cessation Rate by Duration of Pharmacotherapy Use

REFERENCES

- 1 Raupach T, van Schayck C,P. Pharmacotherapy for smoking cessation: current advances and research topics. *CNS Drugs* 2011;**25**(5):371-82.
- 2 Cahill K, Stevens S, Lancaster T. Pharmacological Treatments for Smoking Cessation. *JAMA* 2014;**311**(2):193-4.
- 3 Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2013;**108**(1):193-202.
- 4 West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. *Thorax* 2007;**62**(11):998-1002.
- 5 Cummings KM, Fix B, Celestino P, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. *Journal of Public Health Management and Practice* 2006;**12**(1):37-43.
- 6 Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. *Lancet* 2005;**365**:1849-54.
- 7 Shiffman S, Brockwell SE, Pillitteri JL, et al. Use of smoking-cessation treatments in the United States. *American Journal of Preventive Medicine* 2008;**34**(2):102-11.
- 8 Alberg AJ, Patnaik JL, May JW, et al. Nicotine replacement therapy use among a cohort of smokers. *Journal of addictive diseases* 2005;**24**(1):101-13.
- 9 Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. *American Journal of Public Health* 2007;**97**(8):1503-9.
- 10 Hagimoto A, Nakamura M, Morita T, et al. Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. *Addiction* 2010;**105**(1):164-73.
- 11 Yang J, Hammond D, Driezen P, et al. The use of cessation assistance among smokers from China: Findings from the ITC China Survey. *BMC public health* 2011;**11**(1):75.
- 12 Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. *Tobacco control* 2013;**22**(1):32-7.
- 13 Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *Jama* 2002;**288**(10):1260-4.
- 14 Hughes JR, Peters EN, Naud S. Effectiveness of over-the-counter nicotine replacement therapy: a qualitative review of nonrandomized trials. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2011;**13**(7):512-22.
- 15 Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. *Drug and Alcohol Review* 2008;**27**(5):529-47.

- 1 16 Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the
2 succeeding. *Tobacco control* 2009;**18**(1):43-6.
3
- 4 17 Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may
5 underestimate the effectiveness of stop-smoking medications. *Nicotine & Tobacco Research*
6 2012;**14**(12):1483-7.
7
- 8 18 Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy.
9 *Tobacco control* 2005;**14**(5):346-55.
10
- 11 19 Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population
12 study. *Addiction (Abingdon, England)* 2014;**109**(3):491-9.
13
- 14 20 Raupach T, Brown J, Herbec A, et al. A systematic review of studies assessing the association between
15 adherence to smoking cessation medication and treatment success. *Addiction* 2014;**109**(1):35-43.
16
- 17 21 Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch
18 use and treatment efficacy: Secondary analysis of a 10 week randomized, double-blind, placebo-
19 controlled clinical trial simulating over-the-counter use in adult smokers. *Clinical therapeutics*
20 2008;**30**(10):1852-8.
21
- 22 22 Lee JH, Jones PG, Bybee K, et al. A longer course of varenicline therapy improves smoking cessation
23 rates. *Preventive cardiology* 2008;**11**(4):210-4.
24
- 25 23 U.S. Department of Commerce, Census Bureau. National Cancer Institute and Centers for Disease
26 Control and Prevention Co-sponsored Tobacco Use Supplement to the Current Population Survey (2010-
27 2011). 2012;.
28
- 29 24 U.S. Census Bureau. Current population survey: Design and methodology. *Technical Paper TP63RV,*
30 *Bureau of Labor Statistics and US Census Bureau, Washington DC* October 2006;**2014**(February 10).
31
- 32 25 Gould W. Jackknife estimation. *Stata Technical Bulletin* 1995;**4**(24).
33
- 34 26 The U.S. Census Bureau. Current Population Survey: Imputation of Unreported Data Items.
35 2014;**2014**(03/18).
36
- 37 27 Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal
38 effects. *Stata Journal* 2012;**12**(2).
39
- 40 28 Raupach T, Shahab L, Neubert K, et al. Implementing a hospital-based smoking cessation programme:
41 evidence for a learning effect. *Patient education and counseling* 2008;**70**(2):199-204.
42
- 43 29 Fu SS, Burgess D, van Ryn M, et al. Views on smoking cessation methods in ethnic minority
44 communities: a qualitative investigation. *Preventive medicine* 2007;**44**(3):235-40.
45
- 46 30 Ryan KK, Garrett-Mayer E, Alberg AJ, et al. Predictors of cessation pharmacotherapy use among black
47 and non-Hispanic white smokers. *Nicotine & tobacco research : official journal of the Society for*
48 *Research on Nicotine and Tobacco* 2011;**13**(8):646-52.
49
- 50
51
52
53
54
55
56
57
58
59
60

- 1 31 Cokkinides VE, Ward E, Jemal A, et al. Under-use of smoking-cessation treatments: results from the
2 National Health Interview Survey, 2000. *American Journal of Preventive Medicine* 2005;**28**(1):119-22.
3
- 4 32 Berg CJ, An LC, Kirch M, et al. Failure to report attempts to quit smoking. *Addictive Behaviors*
5 2010;**35**(10):900-4.
6
- 7 33 Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. *Respiratory*
8 *medicine* 2008;**102**(8):1182-92.
9
- 10 34 Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective
11 study of an Australian national sample. *Addiction* 2006;**110**:121-7.
12
- 13 35 Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction*
14 2007;**102**(5):809-14.
15
- 16 36 Pfizer Inc. Getting started with CHANTIX: Things to Remember. 2014;**2014**(March 2014).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Association between duration of use of pharmacotherapy and smoking cessation: Findings from a national survey
Effectiveness of pharmacotherapy for smoking cessation in the general population:
Duration of use matters

Mohammad Siahpush, PhD
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Corresponding author:
Raees A. Shaikh, MPH
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA
Email: raees.shaikh@unmc.edu | Tel: 402-559-1936 | Fax: 402-559-3773

Molly McCarthy, MPH
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Asia Sikora Kessler, PhD
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Melissa Tibbits, PhD
Department of Health Promotion, Social and Behavioral Health
College of Public Health | University of Nebraska Medical Center
984365 Nebraska Medical Center | Omaha, NE 68198-4365 | USA

Gopal K. Singh, Ph.D., M.S., M.Sc.
U.S. Department of Health & Human Services
5600 Fishers lane, Room 18-41 | Rockville, MD 20857 | USA

Word Count: 2582/2496

Key Words: Pharmacotherapy for [Smoking C](#)essation, Duration of Pharmacotherapy [Use](#), Smoking Cessation, Assisted Cessation

Formatted: Highlight

ABSTRACT

AimObjective: To investigate the association of the duration of use of prescription medications and nicotine replacement therapy (NRT) with smoking cessation using a national sample of the general population in the United States, controlling for nicotine dependence and sociodemographic variables.

Setting: United States

Participants:

Methods: We used data from the 2010-2011 Tobacco Use Supplement to the US Current Population Survey. We limited the analysis to current daily smokers who made a quit attempt in the past year and former smokers who were a daily smoker one year prior to the survey (n = 8263). Respondents were asked about duration of use of prescription medication (vVarenicline, bBupropion, other) and NRT (nicotine patch, gum/lozenges, nasal spray, and inhaler) for smoking cessation.

Primary Outcome Measure: Successful Smoking Cessation. Individuals who reported to have smoked at least 100 cigarettes in their lifetime but were not smoking at all at the time of the interview and were a daily smoker one year prior to the interview were considered to have successfully quit smoking.

Results: After adjusting for daily cigarette consumption and sociodemographic covariates, we found ~~overwhelming~~ evidence ($p < 0.001$) for ~~an~~ association between duration of pharmacotherapy use and smoking cessation ($p < 0.001$). Adjusted cessation rates for those who used prescription medication or NRT for 5+ weeks were 28.8% and 27.8%, respectively. Adjusted cessation rates for those who used prescription medication or NRT for

1
2
3
4
5
6
7 less than five weeks varied from 6.2% to 14.5%. Adjusted cessation rates for those who used
8 only behavioral counseling and those who attempted to quit smoking unassisted were 16.1%
9 and 16.4%, respectively.
10

11
12 **Conclusion:** ~~Use of pharmacotherapy for smoking cessation for at least five weeks is~~
13 ~~associated with increased likelihood of successful smoking cessation. can be effective in the~~
14 ~~general population if used for at least five weeks. Results suggest that encouraging smokers~~
15 who intend to quit to use pharmacotherapy and to adhere to treatment duration can help
16 improve chances of a successful cessation.
17
18
19
20
21

22 ARTICLE SUMMARY

23 Strengths and limitations of the study:

- 24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- This was the first population-based study to examine the association between the duration of use of prescription medication as well as NRT for smoking cessation ~~as a~~ predictor of and successful smoking cessation, controlling for nicotine dependence and sociodemographic variables.
 - A strength of this study was that it used a large nationally representative sample with a relatively high response rate.
 - Our results strengthen the findings of clinical trials about the efficacy of pharmacotherapy for smoking cessation and indicate that these aids ~~could~~ might also be effective ~~successful~~ in the general population if they are used for at least five weeks.
 - A strong possibility of reverse causation such that relapse would determine duration of pharmacotherapy use rather than vice versa, was a major limitation of this study. Recall bias, especially related to the smokers previous quit attempts and the observational nature of the study precluding the establishment of a causal link were between the

1
2
3
4
5
6
7 duration of pharmacotherapy use and successful smoking cessation, were the ~~major~~
8 ~~other~~ limitations. ~~of this study.~~
9
10

11 12 13 14 15 INTRODUCTION

16
17 Clinical trials provide strong evidence that pharmacotherapy for smoking cessation
18 including various forms of nicotine replacement therapies (NRT), ~~b~~upropion, or ~~v~~arenicline
19 greatly increase the chances of a successful smoking cessation attempt.[1, 2] However,
20 observational population-based studies have shown mixed results. While some have shown
21 that pharmacotherapy increases smoking cessation rates,[3-6] others have concluded the
22 opposite.[7-11] Yet, other population-based studies have shown no difference in cessation
23 rates between those who use and those who do not use pharmacotherapy.[12, 13] The
24 population-based reports that have found no favorable effect of pharmacotherapy have been
25 criticized for not controlling for nicotine dependence,[14-16] which is a predictor of abstinence
26 and is usually higher among smokers who choose to use pharmacotherapy for smoking
27 cessation.[4, 14, 17, 18] Some of the analyses that have controlled for nicotine dependence
28 have found a favorable effect of pharmacotherapy on smoking cessation[3, 4, 19] but others
29 have not.[7]
30
31
32
33
34
35
36
37
38
39
40
41
42

43 An additional confounder that rarely is taken into account in population-based studies is
44 duration of use of pharmacotherapy, which has been found to be associated with treatment
45 success in clinical trials.[20-22] We know of one population-based study which examined the
46 association of duration of use of pharmacotherapy with smoking cessation and found no
47 association.[12] This study was conducted in the US where NRT can be purchased over the
48
49
50
51
52

1
2
3
4
5
6
7 counter and medications such as [bBupropion](#) and [vVarenicline](#) can only be obtained as
8
9 prescription drugs.

10
11 While clinical trials have high internal validity and can provide evidence for the efficacy
12 of pharmacotherapy, observational population-based studies can address effectiveness of these
13 therapies under conditions that they are intended to be used.[14] Furthermore, while clinical
14 trials provide confidence in causal associations, population-based studies are strong in
15 representativeness and external validity. Thus, both are needed to advance the science of
16 smoking cessation.[19]

17
18 There is no literature on population-based studies that examine the association of
19 duration of NRT and prescription medication use with smoking cessation. Our aim was to use a
20 large representative sample of the general population in the United States and investigate the
21 association of the duration of use of prescription medications and NRT with smoking cessation,
22 controlling for nicotine dependence and sociodemographic variables.

23 24 25 26 27 28 29 30 31 32 33 **METHODS**

34 35 **Data**

36
37 We used data from the 2010-2011 Tobacco Use Supplement to the Current Population
38 Survey (TUS-CPS), sponsored by the National Cancer Institute and administered by the US
39 Census Bureau in May 2010, August 2010, and January 2011.[23] The TUS-CPS is administered
40 as a part of the CPS, which is a monthly national survey of representative households by the US
41 Census Bureau and the Bureau of Labor Statistics.[24] The TUS-CPS utilizes a multistage
42 probability sampling of individuals 15 years and older, from a sample of approximately 56,000
43 housing units, in turn selected from 792 primary sampling units. The average response rate for
44 CPS for the 3 months of surveys used in this study was 93%, whereas for the TUS it was 63%.

Measurements

Successful smoking cessation:

Individuals who reported to have smoked at least 100 cigarettes in their entire life but were not smoking at all at the time of the interview [and were a daily smoker one year prior to the interview](#) (“Around this time 12 months ago were you smoking everyday ...?”) were considered to have successfully quit smoking (n = 1 769). Those who reported to have quit within the last four weeks were excluded from the analysis (n = 322). Individuals who reported to have smoked at least 100 cigarettes in their entire life, were smoking every day at the time of the interview and had made a quit attempt in the past year were considered to have failed in their quit attempt (n = 7 304). Individuals who reported to have used both prescription medication and NRT for smoking cessation were excluded from the analysis (n = 488) because after subdividing this group by categories of duration of use for prescription medication and NRT, some of the subgroup sample sizes were extremely small. The total sample size for the study was 8 263 respondents, consisting of 1 379 who successfully quit smoking and 6 884 whose quit attempt was not successful.

Assisted quit attempt and duration of pharmacotherapy use:

Both daily and former smokers were asked in three separate questions to indicate whether, in their last quit attempt in the past year, they used a prescription pill called (a) Chantix or ~~Varenicline~~[varenicline](#), (b) ~~z~~[Zyban](#), ~~b~~[Bupropion](#), or ~~w~~[Wellbutrin](#), or (b) other prescription pills. They were also asked in three separate questions to indicate whether, in their last quit attempt [in the past year](#), they used (a) a nicotine patch, (b) nicotine gum or nicotine lozenge, or (c) nicotine nasal spray or nicotine inhaler. They were also asked to indicate how many days, weeks or months they used these prescription and/or NRT medications.

1
2
3
4
5
6
7 Furthermore, both daily and former smokers were asked three separate questions about use of
8 behavioral counseling in their last quit attempt in the past year. They were asked if they used a
9 (a) telephone helpline or quitline, (b) one-on-one counseling or (c) stop smoking clinic, class or
10 support group. Based on the questions about use of prescription medication, NRT and
11 behavioral counseling, we created the following two categorical variables:
12
13
14
15

16
17 Method of quit attempt

- 18 • Prescription medication only
- 19 • Prescription medication and behavioral counseling
- 20 • NRT only
- 21 • NRT and behavioral counseling
- 22 • Behavioral counseling only
- 23 • Unassisted

24
25
26
27
28
29
30
31 Duration of use of pharmacotherapy

- 32 • Prescription medication: 5+ weeks
- 33 • Prescription medication: 3-4 weeks
- 34 • Prescription medication: 1-2 weeks¹
- 35 • NRT: 5+ weeks
- 36 • NRT: 3-4 weeks
- 37 • NRT: 1-2 weeks
- 38 • Behavioral counseling only
- 39 • Unassisted

40
41
42
43
44
45
46
47
48
49 We categorized duration of use of pharmacotherapy based on a systematic review of
50 studies assessing adherence to smoking cessation medication.[20] In categorizing duration of
51
52

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

use, we made no distinction between whether or not the medication was combined with behavioral counseling as this distinction was inconsequential in the analysis.

Statistical analysis

We used multivariable logistic regression models to compute adjusted odds ratios for the association of the method of quit attempt and duration of use of pharmacotherapy with successful smoking cessation. Sampling weights were taken into account in the computation of parameter estimates. We computed *p*-values using the jackknife, which is an unbiased estimator for a statistic and a data-dependent method to calculate standard errors.[25] All models controlled for daily cigarette consumption (current daily consumption among daily smokers, and daily consumption 12 months ago among former smokers), age, race/ethnicity, education, occupation, and family income. In order to account for the missing income data, CPS uses one of the three imputation methods, relational imputation, longitudinal edits, or hot deck allocation. Details of these methods are described elsewhere.[26] In multivariable logistic regression models, we omitted observations that had a missing value for any of the covariates. This constituted 1.7% of the full sample in the analysis pertaining to the method of quit attempt (*n* = 142) and 6.3% of the full sample in the analysis pertaining to duration of pharmacotherapy use (*n* = 491). We used the logistic regression results to compute adjusted cessation rates by method of quit attempt and duration of use of pharmacotherapy. These adjusted rates were computed by fixing covariates at their means in the fitted models.[27]

RESULTS

Sample characteristics and bivariate associations

Table 1. Weighted sample characteristics and unadjusted smoking cessation rates across categories of each covariate

Variable	% in sample	% quit	p- value
Method of quit attempt			0.074
Prescription only	10.01	18.54	
Prescription plus behavioral support	1.14	23.8	
NRT only	18.26	14.32	
NRT plus behavioral support	2.54	18.98	
Behavioral only	1.36	18.59	
Unassisted	66.68	17.16	
Duration of pharmacotherapy use			<0.001
Prescription: 5+ weeks	4.9	34.38	
Prescription: 3-4 weeks	1.43	16.82	
Prescription: 1-2 weeks	1.89	15.28	
NRT: 5+ weeks	6.04	30.65	
NRT: 3-4 weeks	1.48	19.9	
NRT: 1-2 weeks	13.48	7.36	
Behavioral only	1.42	18.59	
Unassisted	69.36	17.16	
Cigarettes per day			<0.001
0-9	24.48	15.08	
10-14	30.04	12.58	
15-19	10.31	12.58	
20-29	29.23	21.83	
30+	5.93	29.59	
Sex			0.975
Female	50.12	16.99	
Male	49.88	17.02	
Age			< 0.001
18-24	11.79	15.32	
25-39	33.08	18.17	
40-54	32.33	14.49	
55+	22.8	19.77	
Race/Ethnicity			0.003
Non-Hispanic White	76.17	17.99	
Non-Hispanic Black	11.34	12.98	
Hispanic	7.39	15.73	
Other	5.09	13.15	
Education			<0.001
Less than high school	15.25	13.15	
High school diploma	73.34	16.74	
Bachelor's degree	11.41	23.91	
Occupation			<0.001
Professional	14.33	20.99	
Service	12.31	13.96	
Sales	14.5	18.45	
Farming/construction/production	17.28	13.08	
Unemployed	12.01	13.81	
Not in labor force	29.57	19.24	
Family income			<0.001

<\$25,000	36.27	13.94
\$25,000-\$49,000	31.65	17.21
\$50,000-\$99,000	23.86	19.63
\$100,000+	8.23	22.17
Full sample		17.01

Note: Sample size for each covariate varies from 7 820 to 8 263 depending on the number of missing values for that covariate. [P-values are based on chi-square tests.](#)

Formatted: Font: (Default) Calibri, Italic

Weighted sample characteristics are shown in Table 1. About 66.7% of the sample reported to have made an unassisted quit attempt; 10% used only prescription medication; 1.1% used prescription medication plus behavioral counseling; 18.2% used only NRT; 2.5% used NRT plus behavioral therapy; and 1.3% used only behavioral counseling. When broken down by duration of use, while most of those who used prescription medication did so for five or more weeks, the great majority of those who used NRT did so for 2 weeks or less. The reported number of cigarettes smoked per day was 14 or less for about 54.5% of the sample. Age was distributed with 11.8% of the sample under 25 years of age, 33% between 25-39 years, 32.3% between 40-54 years, and 22.8% 55 years or older. The sample was 76% non-Hispanic white, 11.3% non-Hispanic Black, 7.4% Hispanic, and 5% of other race/ethnicity. About 15.2% of the sample did not have a high school diploma, 73.3% had high school diploma, and 11.4% had at least a bachelor's degree. The distribution of family income was skewed such that over a third of the sample had an income of less than \$25 000 and less than a tenth of the sample had an income of \$100 000 or greater.

Table 1 also provides smoking cessation rates across categories of each covariate, indicating bivariate (unadjusted) associations between the covariates and quitting. Cessation rate was 17% in the whole sample. There was very little evidence that method of quit attempt was associated with cessation rate ($p < 0.074$). However, ~~there was overwhelming evidence that the~~ duration of pharmacotherapy use ~~was associated with quitting~~ ($p < 0.001$), ~~such that the use of prescription medication or NRT for 5+ weeks was associated with remarkably higher cessation rates compared to the use of these products for shorter durations, behavioral counseling or unassisted quit attempts.~~ ~~n~~—Number of cigarettes smoked per day had a curvilinear relationship with cessation such that those who smoked 0-9 cigarettes and those who smoked 20+ cigarettes per day had a higher cessation rate than others ($p < 0.001$), ~~a~~—Age had a curvilinear relationship with cessation in that individuals in the 25-39 and 55+ age categories had notably higher cessation rates than others ($p < 0.001$), ~~and~~ ~~ra~~—Race/ethnicity ($p = 0.003$) ~~werewas~~ all associated with quitting. ~~such that Non-Hispanic Whites had the highest~~

Formatted: Font: (Default) Calibri, Italic

and non-Hispanic Blacks had the lowest cessation rates ($p = 0.003$). Higher socioeconomic status as measured by education, occupation, and income was associated with a higher cessation rate ($p < 0.001$ for all three indicators of socioeconomic status). Sex had no association with cessation.

Adjusted results from multivariable logistic regression models

Table 2 provides adjusted odds ratios for the association of method of quit attempt with the probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence of an association between quitting method and successful cessation, the adjusted results

Table 2. Adjusted^a odds ratios and 95% confidence intervals (CI) for the association of method of quit attempt and duration of pharmacotherapy use with the probability of successful smoking cessation

	OR (95% CI)	p-value
Method of quit attempt (n = 8 121)		
Prescription only	1.00	0.025
Prescription plus behavioral support	1.42 (0.76-2.66)	<u>0.277</u>
NRT only	0.78 (0.59-1.02)	<u>0.072</u>
NRT plus behavioral support	1.17 (0.73-1.86)	<u>0.513</u>
Behavioral only	1.06 (0.57-1.97)	<u>0.844</u>
Unassisted	1.09 (0.87-1.37)	<u>0.464</u>
Duration of pharmacotherapy use (n = 7 772)		
Prescription: 5+ weeks	1.00	< 0.001
Prescription: 3-4 weeks	0.42 (0.21-0.84)	<u>0.014</u>
Prescription: 1-2 weeks	0.38 (0.22-0.66)	<u>0.001</u>
NRT: 5+ weeks	0.95 (0.67-1.36)	<u>0.786</u>
NRT: 3-4 weeks	0.53 (0.29-0.97)	<u>0.040</u>
NRT: 1-2 weeks	0.16 (0.11-0.24)	<u><0.001</u>
Behavioral only	0.47 (0.25-0.90)	<u>0.022</u>
Unassisted	0.48 (0.37-0.64)	<u><0.001</u>

^a Adjusted for the effect of number of cigarettes smoked per day, sex, age, race/ethnicity, education, occupation, and family income.

Figure 1 here.....

Table 2 provides adjusted odds ratios for the association of method of quit attempt with the probability of smoking cessation. Figure 1 shows the adjusted cessation rates for various quitting methods. Unlike the unadjusted results in Table 1 which provided very little evidence

Formatted: Line spacing: 1.5 lines

Formatted: Left, Line spacing: 1.5 lines

Formatted: Font: Not Bold

Formatted: Indent: First line: 0"

1
2
3
4
5
6
7 ~~of an association between quitting method and successful cessation, the adjusted results~~
8 revealed some evidence of an association ($p = 0.025$). The highest cessation rate was among
9 those who used prescription medication and behavioral counseling (20.4%) followed by those
10 who used NRT and behavioral counseling (17.4%), attempted to quit unassisted (16.4%), used
11 behavioral counseling only (16.1%), and those who used prescription medication only (15.3%).
12
13 The lowest cessation rate was among those who only used NRT as a quitting method (12.3%).
14

15
16
17
18 Figure 2 here.....

Formatted: Font: Not Bold

19
20 Table 2 also provides adjusted odds ratios for the association of duration of
21 pharmacotherapy use with the probability of smoking cessation. Figure 2 shows the adjusted
22 cessation rates for various durations of pharmacotherapy use. Consistent with the unadjusted
23 results in Table 1, the adjusted results [in Table 2 also](#) provide **strong** evidence ($p < 0.001$) of an
24 association between duration of pharmacotherapy use and successful cessation. [As shown in](#)
25 [Figure 2, cessation rates were highest among those who used prescription medication for 5+](#)
26 [weeks \(28.8%\) and those who used or NRT for 5+ weeks \(27.8%\) had higher cessation rates,](#)
27 [28.8% and 27.8% respectively, than others.](#) Cessation rates for those who used prescription
28 medication or NRT for less than five weeks varied from 6.2% to 14.5%. Cessation rates for those
29 who used only behavioral counseling and those who attempted to quit smoking unassisted
30 were 16.1% and 16.4%, respectively.
31

32
33 The results pertaining to the association of other covariates with successful cessation
34 were very similar in the multivariable regression models for method of quit attempt and
35 duration of pharmacotherapy use. These results were consistent with bivariate associations
36 reported above, except for the fact that there was very little evidence for an association of
37 race/ethnicity and smoking cessation in multivariable analyses.
38
39

40 41 42 43 44 45 DISCUSSION

46
47 This is the first population-based study to examine the [association of successful smoking](#)
48 [cessation and](#) duration of use of prescription medication as well as NRT for smoking cessation
49 [as a predictor of successful smoking cessation.](#) We found that using pharmacotherapy for five
50 weeks or longer is associated with a **remarkably** higher probability of cessation compared to
51
52

1
2
3
4
5
6
7 using pharmacotherapy for shorter durations, only using behavioral counseling or trying to quit
8 unassisted.
9

10 Our findings are consistent with the results of a study of a hospital-based cessation
11 program where participants who used NRT for 5 weeks or longer were found to have a higher
12 cessation rate at 6-month follow-up.[28] However, our findings are not consistent with those of
13 a population-based study which did not find any evidence that using NRT for more than 6
14 weeks versus not using NRT at all was associated with smoking cessation.[12] In that study, the
15 survey response rate was low, the sample size was small and prescription medications were not
16 examined. These factors could explain the discrepant findings.
17
18
19

20 While we found that smokers who used pharmacotherapy for at least 5 weeks have a far
21 more favorable outcome than others, only 11% of the sample was in this group and notably
22 about 70% of the sample did not use any pharmacotherapy for smoking cessation. Previous
23 research indicates that barriers to the use of these cessation aids include concerns with their
24 addictiveness, cost and side effects, as well as the belief that a treatment of any kind is not
25 needed to quit smoking.[29-31]
26
27
28

29 A major weakness/limitation of the study is that there is a strong possibility of reverse
30 causation such that relapse would determine duration of pharmacotherapy use rather than vice
31 versa.[35] Smokers who use varenicline to quit smoking are asked to completely stop smoking
32 one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a
33 short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit
34 attempt would cause a short duration of pharmacotherapy use instead of the reverse.
35 Furthermore, because of its observational nature, our study cannot establish a causal link
36 between the duration of pharmacotherapy use and successful smoking cessation. While our
37 analyses controlled for several important predictors of cessation including daily cigarette
38 consumption, age, race, education, occupation, and income, it is possible that there might be
39 residual confounding related to variables such as depression, anxiety, alcohol use, and financial
40 stress.[33, 34] Such confounding would further weaken the ability of the study to imply
41 causation.
42
43
44
45
46
47
48

49 Another-weakness of the study relates to the fact that smokers forget many quit
50 attempts [7, 32] and they are more prone to recall attempts that used pharmacotherapy than
51 those that did not.[14, 17] Such recall bias can underestimate the success rate of attempts at
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

quitting with the aid of pharmacotherapy.[17] ~~Another limitation of the study is that because of its observational nature, our study cannot establish a causal link between the duration of pharmacotherapy use and successful smoking cessation. While our analyses controlled for several important predictors of cessation including daily cigarette consumption, age, race, education, occupation, and income, it is possible that there is residual confounding related to variables such as depression, anxiety, alcohol use, and financial stress.[33, 34] Such confounding would further weaken the ability of the study to imply causation. Moreover, there is a possibility of reverse causation such that relapse would determine duration of pharmacotherapy use rather than vice versa.[35] Smokers who use Varenicline to quit smoking are asked to completely stop smoking one week after their quit date.[36] Thus, individuals who use pharmacotherapies and relapse a short while after a quit attempt may stop using these aids. In such cases, an unsuccessful quit attempt would cause a short duration of pharmacotherapy use instead of the reverse.~~

A strength of this study was that it used a large nationally representative sample with a relatively high response rate. This was the first time that questions about the duration of pharmacotherapy use were included in the TUS-CPS. We know of no other national data on the general population that provide information on this variable. Many population-based studies of pharmacotherapies for smoking cessation have found these aids to be ineffective. It is likely that if these studies were able to account for duration of use, their findings would have been different. However, data on duration of use is not routinely collected and it would require a large sample size to provide a reliable estimate of the effect of using these medications for duration of a few weeks. Nonetheless, it would likely be an important area for further research to establish the relationship between duration of use of pharmacotherapy and successful quitting in the general population.

Our results strengthen the findings of clinical trials about the efficacy of pharmacotherapy for smoking cessation and indicate that these aids ~~can~~might also be ~~effective~~successful in the general population if they are used for at least five weeks. ~~Smokers who intend to quit should be encouraged to use pharmacotherapy and adhere to their recommended duration of use.~~

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONTRIBUTORSHIP STATEMENT

We assure that all authors included on a paper fulfill the criteria of authorship. All have contributed in the conception and design, analysis and interpretation of data, drafting of the article and revising it critically for important intellectual content, and final approval of the version to be published. In addition we also assure that there is no one else who fulfills the criteria but has not been included as an author. Dr. Mohammad Siahpush was instrumental in conceptualization of research study, data analysis, and writing of the initial draft of the manuscript. Raees Shaikh and Molly McCarthy contributed in the development of study, data analysis, and preparation of the results section. They also helped with writing the manuscript and editing it for final submission. Dr. Asia Sikora helped with literature review, provided inputs for the materials and method section, and contributed to writing and editing the manuscript. Dr. Melissa Tibbits was involved with literature review and data analysis and provided her inputs to the entire manuscript. Dr. Gopal Singh was involved with formulation of research study and helped in the data analysis and contributed in the writing and editing of the final manuscript.

DETAILS OF FUNDING

This work did not require or receive funding.

CONFLICT OF INTEREST STATEMENT

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) declare that no support was received from any organization for the submitted work and that there was no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, neither did we have other relationships or activities that could appear to have influenced the submitted work. No competing interests to declare.

ETHICAL APPROVAL STATEMENT

No ethical approval was required for this work.

DATA SHARING STATEMENT

No additional data used or available.

FIGURE LEGENDS

15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure1: Adjusted Cessation Rate by Method of Quit Attempt

Figure2: Adjusted Cessation Rate by Duration of Pharmacotherapy Use

REFERENCES

- 1 Raupach T, van Schayck C,P. Pharmacotherapy for smoking cessation: current advances and research topics. *CNS Drugs* 2011;**25**(5):371-82.
- 2 Cahill K, Stevens S, Lancaster T. Pharmacological Treatments for Smoking Cessation. *JAMA* 2014;**311**(2):193-4.
- 3 Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. *Addiction* 2013;**108**(1):193-202.
- 4 West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the “real world”? Findings from a prospective multinational cohort study. *Thorax* 2007;**62**(11):998-1002.
- 5 Cummings KM, Fix B, Celestino P, et al. Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. *Journal of Public Health Management and Practice* 2006;**12**(1):37-43.
- 6 Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. *Lancet* 2005;**365**:1849-54.
- 7 Shiffman S, Brockwell SE, Pillitteri JL, et al. Use of smoking-cessation treatments in the United States. *American Journal of Preventive Medicine* 2008;**34**(2):102-11.
- 8 Alberg AJ, Patnaik JL, May JW, et al. Nicotine replacement therapy use among a cohort of smokers. *Journal of addictive diseases* 2005;**24**(1):101-13.
- 9 Lee CW, Kahende J. Factors associated with successful smoking cessation in the United States, 2000. *American Journal of Public Health* 2007;**97**(8):1503-9.
- 10 Hagimoto A, Nakamura M, Morita T, et al. Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. *Addiction* 2010;**105**(1):164-73.
- 11 Yang J, Hammond D, Driezen P, et al. The use of cessation assistance among smokers from China: Findings from the ITC China Survey. *BMC public health* 2011;**11**(1):75.
- 12 Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. *Tobacco control* 2013;**22**(1):32-7.

- 1
2
3
4
5
6
7 13 Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for
8 smoking cessation. *Jama* 2002;**288**(10):1260-4.
9
10 14 Hughes JR, Peters EN, Naud S. Effectiveness of over-the-counter nicotine replacement therapy: a
11 qualitative review of nonrandomized trials. *Nicotine & tobacco research : official journal of the Society
12 for Research on Nicotine and Tobacco* 2011;**13**(7):512-22.
13
14 15 Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence
15 supporting its effectiveness. *Drug and Alcohol Review* 2008;**27**(5):529-47.
16
17 16 Kotz D, West R. Explaining the social gradient in smoking cessation: it's not in the trying, but in the
18 succeeding. *Tobacco control* 2009;**18**(1):43-6.
19
20 17 Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may
21 underestimate the effectiveness of stop-smoking medications. *Nicotine & Tobacco Research*
22 2012;**14**(12):1483-7.
23
24 18 Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy.
25 *Tobacco control* 2005;**14**(5):346-55.
26
27 19 Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population
28 study. *Addiction (Abingdon, England)* 2014;**109**(3):491-9.
29
30 20 Raupach T, Brown J, Herbec A, et al. A systematic review of studies assessing the association between
31 adherence to smoking cessation medication and treatment success. *Addiction* 2014;**109**(1):35-43.
32
33 21 Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch
34 use and treatment efficacy: Secondary analysis of a 10 week randomized, double-blind, placebo-
35 controlled clinical trial simulating over-the-counter use in adult smokers. *Clinical therapeutics*
36 2008;**30**(10):1852-8.
37
38 22 Lee JH, Jones PG, Bybee K, et al. A longer course of varenicline therapy improves smoking cessation
39 rates. *Preventive cardiology* 2008;**11**(4):210-4.
40
41 23 U.S. Department of Commerce, Census Bureau. National Cancer Institute and Centers for Disease
42 Control and Prevention Co-sponsored Tobacco Use Supplement to the Current Population Survey (2010-
43 2011). 2012;.
44
45 24 U.S. Census Bureau. Current population survey: Design and methodology. *Technical Paper TP63RV,
46 Bureau of Labor Statistics and US Census Bureau, Washington DC* October 2006;**2014**(February 10).
47
48 25 Gould W. Jackknife estimation. *Stata Technical Bulletin* 1995;**4**(24).
49
50 26 The U.S. Census Bureau. Current Population Survey: Imputation of Unreported Data Items.
51 2014;**2014**(03/18).
52
53 27 Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal
54 effects. *Stata Journal* 2012;**12**(2).
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

28 Raupach T, Shahab L, Neubert K, et al. Implementing a hospital-based smoking cessation programme: evidence for a learning effect. *Patient education and counseling* 2008;**70**(2):199-204.

29 Fu SS, Burgess D, van Ryn M, et al. Views on smoking cessation methods in ethnic minority communities: a qualitative investigation. *Preventive medicine* 2007;**44**(3):235-40.

30 Ryan KK, Garrett-Mayer E, Alberg AJ, et al. Predictors of cessation pharmacotherapy use among black and non-Hispanic white smokers. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2011;**13**(8):646-52.

31 Cokkinides VE, Ward E, Jemal A, et al. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. *American Journal of Preventive Medicine* 2005;**28**(1):119-22.

32 Berg CJ, An LC, Kirch M, et al. Failure to report attempts to quit smoking. *Addictive Behaviors* 2010;**35**(10):900-4.

33 Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. *Respiratory medicine* 2008;**102**(8):1182-92.

34 Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: results from a prospective study of an Australian national sample. *Addiction* 2006;**110**:121-7.

35 Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. *Addiction* 2007;**102**(5):809-14.

36 Pfizer Inc. Getting started with CHANTIX: Things to Remember. 2014;**2014**(March 2014).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure1- Adjusted Cessation Rate by Method of Quit Attempt
105x76mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure2- Adjusted Cessation Rate by Duration of Pharmacotherapy Use
105x76mm (300 x 300 DPI)

view only

STROBE Statement Checklist

	Checklist
Title and abstract	Yes
Introduction	
Background/rationale	Yes
Objectives/Aims	Yes
Methods	
Data sources	Yes
Measurement	Yes
Statistical methods	Yes
Results	
Descriptive data	Yes
Main results	Yes
Discussion	
Key results	Yes
Interpretation	Yes
Generalizability/Strengths	Yes
Limitations	Yes
Other information	
Funding	Yes
Competing Interest Statement:	Yes
Ethical Approval Statement	Yes
Contributorship Statement	Yes